

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |   |
|--|--|---|---|
| <b>(51) International Patent Classification<sup>6</sup>:</b><br>C07D 263/32, A61K 31/42, C07D 413/12,<br>C07C 275/28, 275/34, 275/42   |  | <b>A1</b>   | <b>(11) International Publication Number:</b> WO 97/40028<br><b>(43) International Publication Date:</b> 30 October 1997 (30.10.97) |
| <b>(21) International Application Number:</b> PCT/US97/06623   |  | <b>(74) Agents:</b> HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020-1104.(US).  |   |
| <b>(22) International Filing Date:</b> 21 April 1997 (21.04.97)  |  |   |   |
| <b>(30) Priority Data:</b><br>08/636,361 23 April 1996 (23.04.96) US<br>08/801,780 14 February 1997 (14.02.97) US<br>08/832,165 2 April 1997 (02.04.97) US   |  | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |   |
| <b>(71) Applicant:</b> VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).   |  | <b>Published</b><br><i>With international search report.</i>  |   |
| <b>(72) Inventors:</b> ARMISTEAD, David, M.; Five Cutting Drive, Maynard, MA 01574 (US). BADIA, Michael, C.; 20 Meadowbrook Road, Bedford, MA 01730 (US). BEMIS, Guy, W.; 256 Appleton Street, Arlington, MA 02174 (US). BETHIEL, Randy, S.; 28 Haskell Street, Allston, MA 02134 (US). FRANK, Catharine, A.; 374 Simpson Road, Marlborough, MA 01752 (US). NOVAK, Perry, M.; 35 Debbie Lane, Milford, MA 01757 (US). RONKIN, Steven, M.; 39 Bridge Street #14, Watertown, MA 02172 (US). SAUNDERS, Jeffrey, O.; 164 Parker Street, Acton, MA 01720 (US).                          |  |   |   |
| <b>(54) Title:</b> UREA DERIVATIVES AS INHIBITORS OF IMPDH ENZYME  |  |   |   |
| <b>(57) Abstract</b><br>The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds. |  |   |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |   |    |                          |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania                  | ES | Spain                                 | LS | Lesotho                                   | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                               | LT | Lithuania                                 | SK | Slovakia                 |
| AT | Austria                  | FR | France                                | LU | Luxembourg                                | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                 | LV | Latvia                                    | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                        | MC | Monaco                                    | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                               | MD | Republic of Moldova                       | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                 | MG | Madagascar                                | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                | ML | Mali                                      | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                               | MN | Mongolia                                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                               | MR | Mauritania                                | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                | MW | Malawi                                    | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                               | MX | Mexico                                    | US | United States of America |
| CA | Canada                   | IT | Italy                                 | NE | Niger                                     | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                 | NL | Netherlands                               | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                 | NO | Norway                                    | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                            | NZ | New Zealand                               | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's Republic of Korea | PL | Poland                                    |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                     | PT | Portugal                                  |    |                          |
| CN | China                    | KZ | Kazakhstan                            | RO | Romania                                   |    |                          |
| CU | Cuba                     | LC | Saint Lucia                           | RU | Russian Federation                        |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                         | SD | Sudan                                     |    |                          |
| DE | Germany                  | LK | Sri Lanka                             | SE | Sweden                                    |    |                          |
| DK | Denmark                  | LR | Liberia                               | SG | Singapore                                 |    |                          |

## UREA DERIVATIVES AS INHIBITORS OF IMPDH ENZYME

TECHNICAL FIELD OF THE INVENTION

The present invention relates to a novel  
5 class of compounds which inhibit IMPDH. This invention  
also relates to pharmaceutical compositions comprising  
these compounds. The compounds and pharmaceutical  
compositions of this invention are particularly well  
suited for inhibiting IMPDH enzyme activity and  
10 consequently, may be advantageously used as therapeutic  
agents for IMPDH mediated processes. This invention  
also relates to methods for inhibiting the activity of  
IMPDH using the compounds of this invention and related  
compounds.

15

BACKGROUND OF THE INVENTION

The synthesis of nucleotides in organisms is  
required for the cells in those organisms to divide and  
replicate. Nucleotide synthesis in mammals may be  
20 achieved through one of two pathways: the *de novo*

- 2 -

synthesis pathway or the salvage pathway. Different cell types use these pathways to a different extent.

5 Inosine-5'-monophosphate dehydrogenase (IMPDH; EC 1.1.1.205) is an enzyme involved in the *de novo* synthesis of guanosine nucleotides. IMPDH catalyzes the NAD-dependent oxidation of inosine-5'-monophosphate (IMP) to xanthosine-5'-monophosphate (XMP) [Jackson R.C. et. al., Nature, 256, pp. 331-333, (1975)].

10 IMPDH is ubiquitous in eukaryotes, bacteria and protozoa [Y. Natsumeda & S.F. Carr, Ann. N.Y. Acad., 696, pp. 88-93 (1993)]. The prokaryotic forms share 30-40% sequence identity with the human enzyme. Regardless of species, the enzyme follows an ordered 15 Bi-Bi reaction sequence of substrate and cofactor binding and product release. First, IMP binds to IMPDH. This is followed by the binding of the cofactor NAD. The reduced cofactor, NADH, is then released from the product, followed by the product, XMP [S.F. Carr et al., J. Biol. Chem., 268, pp. 27286-90 (1993); E.W. Holmes et al., Biochim. Biophys. Acta, 364, pp. 209-217 20 (1974)]. This mechanism differs from that of most other known NAD-dependent dehydrogenases, which have either a random order of substrate addition or require 25 NAD to bind before the substrate.

Two isoforms of human IMPDH, designated type I and type II, have been identified and sequenced [F.R. Collart and E. Huberman, J. Biol. Chem., 263, pp. 15769-15772, (1988); Y. Natsumeda et. al., J. Biol. Chem., 265, pp. 5292-5295, (1990)]. Each is 514 amino acids, and they share 84% sequence identity. Both 30 IMPDH type I and type II form active tetramers in solution, with subunit molecular weights of 56 kDa [Y.

- 3 -

Yamada et. al., Biochemistry, 27, pp. 2737-2745 (1988)].


The *de novo* synthesis of guanosine nucleotides, and thus the activity of IMPDH, is particularly important in B and T-lymphocytes. These cells depend on the *de novo*, rather than salvage pathway to generate sufficient levels of nucleotides necessary to initiate a proliferative response to mitogen or antigen [A.C. Allison et. al., Lancet II, 1179, (1975) and A.C. Allison et. al., Ciba Found. Symp., 48, 207, (1977)]. Thus, IMPDH is an attractive target for selectively inhibiting the immune system without also inhibiting the proliferation of other cells.

Immunosuppression has been achieved by inhibiting a variety of enzymes including for example, the phosphatase calcineurin (inhibited by cyclosporin and FK-506); dihydroorotate dehydrogenase, an enzyme involved in the biosynthesis of pyrimidines (inhibited by leflunomide and brequinar); the kinase FRAP (inhibited by rapamycin); and the heat shock protein hsp70 (inhibited by deoxyspergualin). [See B. D. Kahan, Immunological Reviews, 136, pp. 29-49 (1993); R. E. Morris, The Journal of Heart and Lung Transplantation, 12(6), pp. S275-S286 (1993)].

Inhibitors of IMPDH are also known. United States patents 5,380,879 and 5,444,072 and PCT publications WO 94/01105 and WO 94/12184 describe mycophenolic acid (MPA) and some of its derivatives as potent, uncompetitive, reversible inhibitors of human IMPDH type I ( $K_i=33$  nM) and type II ( $K_i=9$  nM). MPA has been demonstrated to block the response of B and T-

- 4 -

cells to mitogen or antigen [A. C. Allison et. al., Ann. N. Y. Acad. Sci., 696, 63, (1993)].



5

**MPA**

10      Immunosuppressants, such as MPA, are useful drugs in the treatment of transplant rejection and autoimmune diseases. [R. E. Morris, Kidney Intl., 49, Suppl. 53, S-26, (1996)]. However, MPA is characterized by undesirable pharmacological properties, such as gastrointestinal toxicity and poor bioavailability. [L. M. Shaw, et. al., Therapeutic Drug Monitoring, 17, pp. 690-699, (1995)].

15      Nucleoside analogs such as tiazofurin, ribavirin and mizoribine also inhibit IMPDH [L. Hedstrom, et. al. Biochemistry, 29, pp. 849-854 (1990)]. These compounds, which are competitive inhibitors of IMPDH, suffer from lack of specificity to this enzyme.

20      Mycophenolate mofetil, a prodrug which quickly liberates free MPA *in vivo*, was recently approved to prevent acute renal allograft rejection following kidney transplantation. [L. M. Shaw, et. al., Therapeutic Drug Monitoring, 17, pp. 690-699, (1995); H. W. Sollinger, Transplantation, 60, pp. 225-232 (1995)]. Several clinical observations, however, limit the therapeutic potential of this drug. [L. M. Shaw, et. al., Therapeutic Drug Monitoring, 17, pp. 690-699, (1995)]. MPA is rapidly metabolized to the

- 5 -

inactive glucuronide *in vivo*. [A.C., Allison and E.M. Eugui, Immunological Reviews, 136, pp. 5-28 (1993)]. The glucuronide then undergoes enterohepatic recycling causing accumulation of MPA in the gastrointestinal tract where it cannot exert its IMPDH inhibitory activity on the immune system. This effectively lowers the drug's *in vivo* potency, while increasing its undesirable gastrointestinal side effects.

It is also known that IMPDH plays a role in other metabolic events. Increased IMPDH activity has been observed in rapidly proliferating human leukemic cell lines and other tumor cell lines, indicating IMPDH as a target for anti-cancer as well as immunosuppressive chemotherapy [M. Nagai et. al., Cancer Res., 51, pp. 3886-3890, (1991)]. IMPDH has also been shown to play a role in the proliferation of smooth muscle cells, indicating that inhibitors of IMPDH, such as MPA or rapamycin, may be useful in preventing restenosis or other hyperproliferative vascular diseases [C. R. Gregory et al., Transplantation, 59, pp. 655-61 (1995); PCT publication WO 94/12184; and PCT publication WO 94/01105].

Additionally, IMPDH has been shown to play a role in viral replication in some viral cell lines. [S.F. Carr, J. Biol. Chem., 268, pp. 27286-27290 (1993)]. Analogous to lymphocyte and tumor cell lines, the implication is that the *de novo*, rather than the salvage, pathway is critical in the process of viral replication.

The IMPDH inhibitor ribavirin is currently being evaluated for the treatment of hepatitis-C virus (HCV) and hepatitis-B virus (HBV) infection and disease. Ribavirin enhances the sustained efficacy of

- 6 -

interferon in HBV and HCV treatment. However, the therapeutic potential of ribavirin is limited by its lack of a sustained response in monotherapy and broad cellular toxicity.

5                   Thus, there remains a need for potent IMPDH inhibitors with improved pharmacological properties. Such inhibitors would have therapeutic potential as immunosuppressants, anti-cancer agents, anti-vascular hyperproliferative agents, antiinflammatory agents, 10 antifungal agents, antipsoriatic and anti-viral agents.

#### SUMMARY OF THE INVENTION

The present invention provides compounds, and 15 pharmaceutically acceptable derivatives thereof, that are useful as inhibitors of IMPDH. These compounds can be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatories, antibiotics, and immunosuppressants for the treatment or prophylaxis of 20 transplant rejection and autoimmune disease. Additionally, these compounds are useful, alone or in combination with other agents, as therapeutic and prophylactic agents for antiviral, anti-tumor, anti-cancer, anti- inflammatory agents, antifungal agents, 25 antipsoriatic immunosuppressive chemotherapy and restenosis therapy regimens.

The invention also provides pharmaceutical 30 compositions comprising the compounds of this invention, as well as multi-component compositions comprising additional IMPDH compounds together with an immunosuppressant. The invention also provides methods of using the compounds of this invention, as well as other related compounds, for the inhibition of IMPDH.

- 7 -

The compounds of this invention, as well as those used in the methods of this invention demonstrate a different metabolic profile than MPA and its derivatives. Because of this difference, methods of this invention and the compounds used therein may offer advantages as therapeutics for IMPDH mediated disease. These advantages include increased overall therapeutic benefit and reduction in deleterious side effects.

10

DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be more fully understood, the following detailed description is set forth. In the description, the following abbreviations are used:

|    | <u>Designation</u> | <u>Reagent or Fragment</u>                                  |
|----|--------------------|---|
|    | Ac                 | acetyl  |
|    | Me                 | methyl  |
|    | Et                 | ethyl   |
| 20 | Bn                 | benzyl  |
|    | CDI                | carbonyldiimidazole   |
|    | DIEA               | diisopropylethylamine                                       |
|    | DMAP               | dimethylaminopyridine                                       |
|    | DMF                | dimethylformamide   |
| 25 | DMSO               | dimethylsulfoxide   |
|    | EDC                | 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride |
|    | EtOAc              | ethyl acetate   |
|    | THF                | tetrahydrofuran   |

30

The following terms are employed herein: Unless expressly stated to the contrary, the terms "-SO<sub>2</sub>-" and "-S(O)<sub>2</sub>-" as used herein refer to a

- 8 -

sulfone or sulfone derivative (i.e., both appended groups linked to the S), and not a sulfinate ester.

The terms "halo" or "halogen" refer to a radical of fluorine, chlorine, bromine or iodine.

5 The term "immunosuppressant" refers to a compound or drug which possesses immune response inhibitory activity. Examples of such agents include cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, 10 mycophenolate mofetil, OKT3, ATAG, interferon and mizoribine.

The term "interferon" refers to all forms of interferons, including but not limited to alpha, beta and gamma forms.

15 IMPDH-mediated disease refers to any disease state in which the IMPDH enzyme plays a regulatory role in the metabolic pathway of that disease. Examples of IMPDH-mediated disease include transplant rejection and 20 autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, and inflammatory bowel disease, as well as inflammatory diseases, cancer, viral replication diseases and vascular diseases.

25 For example, the compounds, compositions and methods of using them of this invention may be used in the treatment of transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells), bone marrow, cornea, small bowel and skin allografts and heart valve xenografts) and autoimmune diseases, such 30 as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitis), lupus, diabetes, mellitus myasthenia gravis, psoriasis, dermatitis, eczema, seborrhoea, pulmonary inflammation, eye uveitis,

- 9 -

hepatitis, Grave's disease, Hashimoto's thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes/mouth), pernicious or immunohaemolytic anaemia, idiopathic adrenal insufficiency, polyglandular autoimmune syndrome, and glomerulonephritis, scleroderma, lichen planus, viteligo (depigmentation of the skin), autoimmune thyroiditis, and alveolitis, inflammatory diseases such as osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma and adult respiratory distress syndrome, as well as in the treatment of cancer and tumors, such as solid tumors, lymphomas and leukemia, vascular diseases, such as restenosis, stenosis and atherosclerosis, and DNA and RNA viral replication diseases, such as retroviral diseases, and herpes.

Additionally, IMPDH enzymes are also known to be present in bacteria and thus may regulate bacterial growth. As such, the IMPDH-inhibitor compounds, compositions and methods described herein may be useful in treatment or prevention of bacterial infection, alone or in combination with other antibiotic agents.

The term "treating" as used herein refers to the alleviation of symptoms of a particular disorder in a patient or the improvement of an ascertainable measurement associated with a particular disorder. As used herein, the term "patient" refers to a mammal, including a human.


The term "thiocarbamates" refers to compounds containing the functional group N-SO<sub>2</sub>-O.

The terms "HBV", "HCV" and "HGV" refer to hepatitis-B virus, hepatitis-C virus and hepatitis-G virus, respectively.

- 10 -

According to one embodiment, the invention provides methods of inhibiting IMPDH activity in a mammal comprising the step of administering to said mammal, a compound of formula I:

5



(I)

wherein:


10 A is selected from:

(C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>6</sub>)-straight or branched alkenyl or alkynyl; and A optionally comprises up to 2 substituents, wherein:

15 the first of said substituents, if present, is selected from R<sup>1</sup> or R<sup>3</sup>, and

the second of said substituents, if present, is R<sup>1</sup>;

20 B is a saturated, unsaturated or partially saturated monocyclic or bicyclic ring system optionally comprising up to 4 heteroatoms selected from N, O, or S and selected from the formulae:



25 wherein each X is the number of hydrogen atoms necessary to complete proper valence;

- 11 -

and B optionally comprises up to 3 substituents,  
wherein:

the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

5 the second of said substituents, if present,  
is selected from R<sup>1</sup> or R<sup>4</sup>, and

the third of said substituents, if present,  
is R<sup>1</sup>; and

D is selected from C(O), C(S), or S(O)<sub>2</sub>;

10 wherein:

each R<sup>1</sup> is independently selected from 1,2-methylenedioxy, 1,2-ethylenedioxy, R<sup>6</sup> or (CH<sub>2</sub>)<sub>n</sub>-Y;

wherein n is 0, 1 or 2; and

Y is selected from halogen, CN, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>,

15 OH, SR<sup>6</sup>, S(O)R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, NH<sub>2</sub>, NHR<sup>6</sup>, N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>R<sup>8</sup>, COOH,  
COOR<sup>6</sup> or OR<sup>6</sup>;

each R<sup>2</sup> is independently selected from (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>)-straight or branched alkenyl or alkynyl; and each R<sup>2</sup> optionally comprises up to 2 substituents, wherein:

the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup>, and

the second of said substituents, if present,  
is R<sup>1</sup>;

25 R<sup>3</sup> is selected from a monocyclic or a bicyclic ring system consisting of 5 to 6 members per ring,  
wherein said ring system optionally comprises up to 4 heteroatoms selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to any of said N, O, or S heteroatoms is  
30 optionally substituted with C(O); and each R<sup>3</sup> optionally comprises up to 3 substituents, wherein:

- 12 -

the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

the second of said substituents, if present,  
is selected from R<sup>1</sup> or R<sup>4</sup>, and

5 the third of said substituents, if present,  
is R<sup>1</sup>;

each R<sup>4</sup> is independently selected from OR<sup>5</sup>,  
OC(O)R<sup>6</sup>, OC(O)R<sup>5</sup>, OC(O)OR<sup>6</sup>, OC(O)OR<sup>5</sup>, OC(O)N(R<sup>6</sup>)<sub>2</sub>,  
OP(O)(OR<sup>6</sup>)<sub>2</sub>, SR<sup>6</sup>, SR<sup>5</sup>, S(O)R<sup>6</sup>, S(O)R<sup>5</sup>, SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>5</sup>,  
10 SO<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, SO<sub>3</sub>R<sup>6</sup>, C(O)R<sup>5</sup>, C(O)OR<sup>5</sup>, C(O)R<sup>6</sup>,  
C(O)OR<sup>6</sup>, NC(O)C(O)R<sup>6</sup>, NC(O)C(O)R<sup>5</sup>, NC(O)C(O)OR<sup>6</sup>,  
NC(O)C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)N(OR<sup>6</sup>)R<sup>6</sup>,  
C(O)N(OR<sup>6</sup>)R<sup>5</sup>, C(NOR<sup>6</sup>)R<sup>6</sup>, C(NOR<sup>6</sup>)R<sup>5</sup>, N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>C(O)R<sup>1</sup>,  
NR<sup>6</sup>C(O)R<sup>6</sup>, NR<sup>6</sup>C(O)R<sup>5</sup>, NR<sup>6</sup>C(O)OR<sup>6</sup>, NR<sup>6</sup>C(O)OR<sup>5</sup>,  
15 NR<sup>6</sup>C(O)N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>C(O)NR<sup>5</sup>R<sup>6</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>5</sup>,  
NR<sup>6</sup>SO<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, N(OR<sup>6</sup>)R<sup>6</sup>, N(OR<sup>6</sup>)R<sup>5</sup>,  
P(O)(OR<sup>6</sup>)N(R<sup>6</sup>)<sub>2</sub>, and P(O)(OR<sup>6</sup>)<sub>2</sub>;

20 each R<sup>5</sup> is a monocyclic or a bicyclic ring system  
consisting of 5 to 6 members per ring, wherein said  
ring system optionally comprises up to 4 heteroatoms  
selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to  
said N, O or S maybe substituted with C(O); and each R<sup>5</sup>  
optionally comprises up to 3 substituents, each of  
which, if present, is R<sup>1</sup>;

25 each R<sup>6</sup> is independently selected from H, (C<sub>1</sub>-C<sub>4</sub>) -  
straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>) straight or  
branched alkenyl; and

each R<sup>6</sup> optionally comprises a substituent that is R<sup>7</sup>,

30 R<sup>7</sup> is a monocyclic or a bicyclic ring system  
consisting of 5 to 6 members per ring, wherein said

- 13 -

ring system optionally comprises up to 4 heteroatoms selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to said N, O or S maybe substituted with C(O); and each R<sup>7</sup> optionally comprises up to 2 substituents independently chosen from H, (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, (C<sub>2</sub>-C<sub>4</sub>) straight or branched alkenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH<sub>2</sub>)<sub>n</sub>-Z;

wherein n is 0, 1 or 2; and

10 Z is selected from halogen, CN, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, OH, S(C<sub>1</sub>-C<sub>4</sub>)-alkyl, SO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl, N((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, N((C<sub>1</sub>-C<sub>4</sub>)-alkyl)R<sup>8</sup>, COOH, C(O)O(C<sub>1</sub>-C<sub>4</sub>)-alkyl or O(C<sub>1</sub>-C<sub>4</sub>)-alkyl; and

15 R<sup>8</sup> is an amino protecting group; and

wherein any carbon atom in any A, R<sup>2</sup> or R<sup>6</sup> is 15 optionally replaced by O, S, SO, SO<sub>2</sub>, NH, or N(C<sub>1</sub>-C<sub>4</sub>)-alkyl.

20 The term "substituted" refers to the replacement of one or more hydrogen radicals in a given structure with a radical selected from a specified group. When more than one hydrogen radical may be replaced with a substituent selected from the same specified group, the substituents may be either the same or different at every position.

25 The term "monocyclic or bicyclic ring system consisting of 5 to 6 members per ring" refers to 5 or 6 member monocyclic rings and 8, 9 and 10 membered bicyclic ring structures, wherein each bond in each ring may be possess any degree of saturation that is 30 chemically feasible. When such structures contain substituents, those substituents may be at any position of the ring system, unless otherwise specified.

- 14 -


As specified, such ring systems may 5  
optionally comprise up to 4 heteroatoms selected from  
N, O or S. Those heteroatoms may replace any carbon  
atoms in these ring systems as long as the resulting  
compound is chemically stable.

The term "wherein each X is the number of  
hydrogen atoms necessary to complete proper valence"  
means that X is 0, 1 or 2 hydrogen atoms, depending  
upon the identity of the ring atom to which X is bound  
10 (C, N, O or S), the identity of the two adjacent ring  
atoms, and the nature of the bonds between the ring  
atom to which X is bound and the two adjacent ring  
atoms (single, double or triple bond). In essence,  
this definition is meant to exclude from X any  
15 substituents other than hydrogen.

The term "amino protecting group" refers to a  
suitable chemical group which may be attached to a  
nitrogen atom. The term "protected" refers to when the  
designated functional group is attached to a suitable  
chemical group (protecting group). Examples of  
20 suitable amino protecting groups and protecting groups  
are described in T.W. Greene and P.G.M. Wuts,  
Protective Groups in Organic Synthesis, 2d. Ed., John  
Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser  
25 and Fieser's Reagents for Organic Synthesis, John Wiley  
and Sons (1994); L. Paquette, ed. Encyclopedia of  
Reagents for Organic Synthesis, John Wiley and Sons  
(1995) and are exemplified in certain of the specific  
compounds used in the invention.

30 According to another embodiment, the  
invention provides methods of inhibiting IMPDH in  
mammals by administering a compound of the formula  
(II):


- 15 -



wherein B and D are as defined above.

More preferably, in methods employing the  
 5 compounds of formulae (I) or (II), component B  
 comprises from 0 to 2 substituents. According to an  
 alternate embodiment, the invention provides methods  
 for inhibiting IMPDH in a mammal employing compounds  
 (I) or (II), wherein B comprises at least a single  
 10 substituent selected from the group defined by R<sup>5</sup>.  
 Preferably, in this embodiment, B is a monocyclic  
 aromatic ring containing at least one substituent which  
 is also a monocyclic aromatic ring.


The present invention also provides compounds  
 15 which are useful in inhibiting IMPDH. According to one  
 embodiment, the IMPDH inhibitory compound has the  
 formula (III):



20 wherein A, B and D are as defined above;  
 E is oxygen or sulfur; and  
 G and G' are independently selected from R<sup>1</sup> or  
 hydrogen.


25 According to an alternate embodiment, the  
 invention provides a compound of the formula (IV):

- 16 -



(IV)

wherein B, D, E, G and G' are defined as above and B' is a saturated, unsaturated or partially saturated monocyclic or bicyclic ring system optionally comprising up to 4 heteroatoms selected from N, O, or S and selected from the formulae:



wherein each X is the number of hydrogen atoms necessary to complete proper valence; and B' optionally comprises up to 3 substituents, wherein:

the first of said substituents, if present, is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

the second of said substituents, if present, is selected from R<sup>1</sup> or R<sup>4</sup>, and


the third of said substituents, if present, is R<sup>1</sup>; wherein X, R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are defined as above.

Excluded from this invention are compounds of formula (IV) wherein B and B' are simultaneously unsubstituted phenyl and compounds wherein B is

- 17 -

unsubstituted phenyl and B' is tri-chloro-, tri-bromo or tri-iodo phenyl.

Preferably, in compounds of formula (IV), B and B' are phenyl groups comprising at least one substituent each. These compounds are represented by formula (V):



wherein K is selected from R<sup>1</sup> or R<sup>4</sup>; and J is selected from R<sup>1</sup>, R<sup>2</sup> or R<sup>4</sup>.

Preferred compounds of formula (V) are those wherein D is -C(O)-, those wherein E is oxygen; those wherein J is NR<sup>6</sup>C(O)R<sup>5</sup> or NR<sup>6</sup>C(O)R<sup>6</sup>, preferably NR<sup>6</sup>C(O)R<sup>6</sup>, more preferably N(CH<sub>3</sub>)C(O)R<sup>6</sup>, and more preferably N(CH<sub>3</sub>)C(O)CH<sub>3</sub>; those wherein K is (CH<sub>2</sub>)<sub>n</sub>-Y, preferably OCH<sub>3</sub> (i.e., n is 0, Y is OR<sup>6</sup>, and R<sup>6</sup> is CH<sub>3</sub>); and those wherein G is hydrogen. More preferred compounds of formula (V) are those wherein:

E is oxygen

J is NR<sup>6</sup>C(O)R<sup>5</sup> or NR<sup>6</sup>C(O)R<sup>6</sup>;

K is (CH<sub>2</sub>)<sub>n</sub>-Y; and

G is hydrogen.

Even more preferred compounds of formula (V) are those wherein:

D is -C(O)-;

E is oxygen;

J is NR<sup>6</sup>C(O)R<sup>6</sup>;

- 18 -

K is  $\text{OCH}_3$ ; and

G is hydrogen.


Most preferably in such compounds, J is  $N(CH_3)C(O)R^6$ .

Alternate preferred compounds are those

5 formula V: wherein J is R<sup>2</sup>, those wherein D is -C(O)-, those wherein E is oxygen, those wherein J is R<sup>2</sup> substituted with R<sup>4</sup>, preferably wherein R<sup>4</sup> is NR<sup>6</sup>C(O)OR<sup>5</sup> or NR<sup>6</sup>C(O)OR<sup>6</sup>, more preferably wherein R<sup>4</sup> is NR<sup>6</sup>C(O)OR<sup>5</sup>, more preferably wherein R<sup>4</sup> is NHC(O)OR<sup>5</sup>,  
10 and more preferably wherein R<sup>4</sup> is NHC(O)O-3-tetrahydrofuryl, those wherein K is (CH<sub>2</sub>)<sub>n</sub>-Y, preferably wherein K is OCH<sub>3</sub>, those wherein G is hydrogen, and those wherein:

15                    D is  $-C(O)-$ ;  
                  E is oxygen;  
                  K is  $OCH_3$ ; and  
                  G is hydrogen.

20 Alternatively, other preferred compounds include those of formula VI:




VI

- 19 -

those compounds of formula VI wherein K is OCH<sub>3</sub>, and those compounds of formula VI wherein G is hydrogen.

An alternate embodiment of this invention is compounds of formula V wherein K is selected from R<sup>1</sup> or R<sup>4</sup>; and J is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, and R<sup>9</sup> wherein, 5 R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup>, are as defined above and R<sup>9</sup> is independently selected from (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>)-straight or branched alkenyl or alkynyl; and each R<sup>9</sup> optionally comprises up to 2 10 substituents selected from NR<sup>6</sup>C(O)OR<sup>10</sup>, wherein R<sub>6</sub> is as defined above and R<sup>10</sup> is selected from (C<sub>1</sub>-C<sub>5</sub>)- straight or branched alkyl optionally comprising up to two substituents selected from NR<sup>6</sup>R<sup>8</sup>, SR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, - (CH<sub>2</sub>)<sub>n</sub>-SR<sup>6</sup>, - (CH<sub>2</sub>)<sub>n</sub>-OR<sup>6</sup>, and OR<sup>6</sup>, wherein n, R<sup>6</sup> and 15 R<sup>8</sup>, are as defined above.

In another embodiment, preferred compounds are those of formula VII:



VII

20

wherein K is selected from R<sup>1</sup> and R<sup>4</sup>; and A, D, R<sup>1</sup> and R<sup>4</sup> are each independently as defined in claim 1.

25

- 20 -


More preferred compounds of formula VII are those wherein D is  $-C(O)-$ , those wherein A is a monocyclic aromatic ring substituted with 1-2 substituents selected from the group consisting of

5       $NR^6C(O)R^6$ ,  $NR^6C(O)R^5$ ,  $CH_2NR^6C(O)OR^6$ , and  $CH_2NR^6C(O)OR^5$ , those wherein A is a monocyclic aromatic ring substituted with 1-2 substituents selected from the group consisting of  $CH_2NR^6C(O)OR^6$  and  $CH_2NR^6C(O)OR^5$ , those A is a monocyclic aromatic ring substituted with

10      $CH_2NR^6C(O)OR^5$ , those wherein A is a monocyclic aromatic ring substituted with  $CH_2NHC(O)OR^5$ , those wherein A is a monocyclic aromatic ring substituted with  $CH_2NHC(O)O-3$ -tetrahydrofuryl, those wherein K is  $(CH_2)_n-Y$ , those wherein K is  $OCH_3$ , and those wherein:

15     A is a monocyclic aromatic ring substituted with  $CH_2NHC(O)O-3$ -tetrahydrofuryl; and K is  $OCH_3$ .


20     Alternatively, other preferred compounds of this invention include those compounds of formula VIII:



VIII

25     wherein D and K are as defined in claim 1.

Another embodiment is those compounds of formula IX:



wherein:


5        D is selected from C(O), C(S) and S(O)2;  
       K is selected from R<sup>1</sup> and R<sup>4</sup>; and  
       J is selected from R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup>.

More preferred compounds of formula IX include  
 10      those wherein D is -C(O)-, those wherein J is NR<sup>6</sup>C(O)R<sup>5</sup>  
           or NR<sup>6</sup>C(O)R<sup>6</sup>, those wherein J is NR<sup>6</sup>C(O)R<sup>6</sup>, those  
           wherein J is N(CH<sub>3</sub>)C(O)R<sup>6</sup>, those wherein J is  
           N(CH<sub>3</sub>)C(O)CH<sub>3</sub>, those wherein K is (CH<sub>2</sub>)<sub>n</sub>-Y, those  
           wherein K is OCH<sub>3</sub>, and those wherein:  
 15      K is OCH<sub>3</sub>; and  
           J is N(CH<sub>3</sub>)C(O)CH<sub>3</sub>.

Tables IA, IB and IIB list preferred  
 individual compounds of the invention and preferred  
 20      compounds employed in the compositions and methods of  
           this invention. Table IIA lists preferred compounds  
           employed in the methods of this invention.

- 22 -


Table IA



| # | G | K | A      |
|---|---|---|--------|
| 1 | H | H | benzyl |

5

Table IB



10

| #  | G | K | B'                               |
|----|---|---|----------------------------------|
| 2  | H | H | 3-methoxyphenyl                  |
| 3  | H | H | 3-thienyl                        |
| 4  | H | H | 3,4-difluorophenyl               |
| 5  | H | H | 2,5-dimethoxyphenyl              |
| 6  | H | H | 3-methylthiophenyl               |
| 7  | H | H | 3-bromophenyl                    |
| 8  | H | H | 3-cyanophenyl                    |
| 9  | H | H | 3-trifluoromethyl-4-chlorophenyl |
| 10 | H | H | 2-methyl-3-chlorophenyl          |
| 11 | H | H | 2-methoxy-5-methylphenyl         |
| 12 | H | H | 2-methoxyphenyl                  |
| 13 | H | H | 3-methoxyphenyl                  |
| 14 | H | H | 2,5-dimethoxyphenyl              |
| 15 | H | H | 3-nitrophenyl                    |
| 16 | H | H | 4-nitrophenyl                    |
| 17 | H | H | 3-methylphenyl                   |
| 18 | H | H | 3-trifluoromethylphenyl          |
| 19 | H | H | 2-trifluoromethylphenyl          |
| 20 | H | H | 3-fluorophenyl                   |
| 21 | H | H | 4-phenoxyphenyl                  |
| 22 | H | H | 3-chlorophenyl                   |


| #  | G | K         | B'                                |
|----|---|-----------|-----------------------------------|
| 23 | H | H         | 3-chloro-4-fluorophenyl           |
| 24 | H | H         | 3-aminophenyl                     |
| 25 | H | H         | 3-(hydroxymethyl)phenyl           |
| 26 | H | H         | 3-acetylenylphenyl                |
| 27 | H | H         | 3-hydroxyphenyl                   |
| 29 | H | H         | 3-pyridinyl                       |
| 30 | H | H         | 4-pyridinyl                       |
| 31 | H | H         | 2-(5-methyl)thiazolyl             |
| 39 | H | H         | 3,4-ethylenedioxyphenyl           |
| 40 | H | H         | 3-methyl-4-nitrophenyl            |
| 41 | H | H         | 3-trifluoromethyl-4-nitrophenyl   |
| 42 | H | 3-chloro  | phenyl                            |
| 43 | H | 3-chloro  | 3-methylphenyl                    |
| 44 | - | -         | -                                 |
| 45 | H | 3-fluoro  | phenyl                            |
| 46 | H | 3-fluoro  | 3-methylphenyl                    |
| 47 | H | H         | 3-carbomethoxymethylphenyl        |
| 48 | H | H         | 3-carboxyethylphenyl              |
| 49 | H | H         | 3-dimethylaminophenyl             |
| 50 | H | H         | 3-[2-(2-methyl)dioxolanyl]phenyl  |
| 51 | H | H         | 3-aminocarbonylphenyl             |
| 53 | H | H         | 3-(3-furanyl)-phenyl              |
| 54 | H | H         | 3-carboxymethylphenyl             |
| 55 | H | 3-methoxy | 3-methylphenyl                    |
| 56 | H | 3-methoxy | 3-nitrophenyl                     |
| 57 | H | 3-chloro  | 3-carbomethoxymethylphenyl        |
| 58 | H | H         | 3-amino-5-methylphenyl            |
| 59 | H | 3-methoxy | 3-aminophenyl                     |
| 60 | H | 3-bromo   | 3-methylphenyl                    |
| 61 | H | 3-chloro  | 3-chloro-4-(5-oxazolyl)phenyl     |
| 62 | H | 3-chloro  | 4-(2-methylpyridyl)               |
| 63 | H | 3-chloro  | 3-carboxymethylphenyl             |
| 64 | H | 3-bromo   | 3-nitrophenyl                     |
| 65 | H | 3-bromo   | 3-aminophenyl                     |
| 66 | H | H         | 3-[5-(2-methylpyrimidinyl)]phenyl |
| 67 | H | H         | 3-(5-oxazolyl)phenyl              |
| 68 | H | 3-chloro  | 2-thienyl                         |
| 69 | H | 3-chloro  | 3-thienyl                         |
| 71 | H | 3-chloro  | 3-methoxycarbamoyl-phenyl         |
| 72 | H | 3-chloro  | 3-acetamidophenyl                 |
| 73 | H | 3-chloro  | 3-iodophenyl                      |
| 74 | H | 3-methyl  | phenyl                            |

- 24 -

| #   | G      | K               | B'  |
|-----|--------|-----------------|---|
| 75  | H      | 3-methyl        | 3-methylphenyl  |
| 76  | methyl | 3-chloro        | 3-methylphenyl  |
| 77  | methyl | H               | 3-methylphenyl  |
| 78  | H      | 3-chloro        | 3-nitrophenyl   |
| 79  | H      | 3-chloro        | 3-aminophenyl   |
| 80  | H      | H               | 3-<br>(cyclohexylsulfamoyl)phenyl                       |
| 81  | H      | H               | 3-(methylsulfamoyl)phenyl                               |
| 82  | H      | H               | 3-(phenylsulfamoyl)phenyl                               |
| 83  | H      | 3-methoxy       | 3-benzyloxycarbamoyl-phenyl                             |
| 84  | H      | 3-methoxy       | 3-acetamidophenyl                                       |
| 85  | H      | 3-chloro        | 4-(2-methyl)furanyl                                     |
| 86  | H      | 3-chloro        | 5-(2-methyl)thienyl                                     |
| 88  | H      | 3-carbomethoxy  | 3-methylphenyl  |
| 89  | H      | 3-carbomethoxy  | 3-nitrophenyl   |
| 91  | H      | 3-chloro        | 4-(2-nitro)thienyl                                      |
| 92  | H      | 3-chloro        | 4-(2-hydroxyamino)thienyl                               |
| 93  | H      | 3-chloro        | 3-(N-methyl)trifluoroacetamido-phenyl                   |
| 94  | H      | 3-chloro        | 3-(methylamino)phenyl                                   |
| 95  | H      | 3-chloro        | 4-(2-amino)thienyl                                      |
| 96  | H      | 3-methoxy       | 3-trifluoroacetamidophenyl                              |
| 97  | H      | 3-methoxy       | 3-(N-methyl)trifluoroacetamido-phenyl                   |
| 98  | H      | 3-methoxy       | 3-(3'-picolyloxycarbamoyl)phenyl                        |
| 99  | H      | 3-methoxy       | 3-(phenoxy carbamoyl)phenyl                             |
| 100 | H      | 3-methoxy       | 3-difluoroacetamidophenyl                               |
| 101 | H      | 3-acetoxymethyl | 3-methylphenyl  |
| 102 | H      | 3-hydroxymethyl | 3-methylphenyl  |
| 104 | H      | H               | 3-nitro-4-fluorophenyl                                  |
| 105 | H      | 3-methoxy       | 3-(aminomethyl)phenyl<br>[•TFA]                         |
| 106 | H      | 3-methoxy       | 5-(N-acetoxy)indolinyl                                  |
| 107 | H      | 3-methoxy       | 3-(N-methyl)acetamidophenyl                             |
| 108 | H      | 3-methoxy       | 3-[(2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl)amino]phenyl |
| 109 | H      | 3-amino         | 3-methylphenyl  |
| 110 | H      | 3-methoxy       | 3-benzamidophenyl                                       |
| 111 | H      | 3-methoxy       | 3-phenylacetamidophenyl                                 |
| 112 | H      | 3-methoxy       | 3-phenylureidophenyl                                    |
| 113 | H      | 3-methoxy       | 3-(t-butoxycarbamoyl)                                   |

- 25 -

| #   | G | K         | B'  |
|-----|---|-----------|---|
| 114 | H | 3-methoxy | methyl)phenyl<br>3-(cyclopentylacetamido)<br>phenyl |
| 115 | H | 3-methoxy | 3-methylphenyl                                      |

Table IC

5


| Compound | L                                  |
|----------|------------------------------------|
| 116      | NHC(O)O-t-butyl                    |
| 117      | NCH <sub>3</sub> C(O)O-t-butyl     |
| 118      | NHC(O)O-methyl                     |
| 119      | NHC(O)O-phenyl                     |
| 120      | NHC(O)O-(S)-3-tetrahydrofuryl      |
| 121      | NHC(O)O-2-picolinyl                |
| 122      | NHC(O)O-(S)-5-oxazolidinonylmethyl |
| 123      | NHC(O)O-4-carbomethoxyphenyl       |
| 124      | NHC(O)O-isobutyl                   |
| 125      | NHC(O)O-allyl                      |
| 126      | NHC(O)O-5-(1,3-dioxanyl)           |
| 127      | NHC(O)O-4-acetamidophenyl          |
| 128      | NHC(O)O-2-furfuryl                 |
| 129      | NHC(O)O-2-thiofurfuryl             |
| 130      | NHC(O)O-2-methoxyethyl             |
| 131      | NHC(O)O-4-tetrahydropyranyl        |
| 132      | NHC(O)O-cyclohexyl                 |
| 133      | NHC(O)O-cyclopentyl                |
| 134      | NHC(O)O-2-hydroxyethyl             |
| 135      | NHC(O)O-cyclohexylmethyl           |
| 136      | NHC(O)O-(R,S)-3-tetrahydrofuryl    |
| 137      | NHC(O)O-3-pyridyl                  |
| 138      | NHC(O)O-benzyl                     |
| 139      | NHC(O)O-3-(tBOC-amino)propyl       |
| 140      | NHC(O)O-4-hydroxybutyl             |
| 141      | NHC(O)O-5-hydroxypentyl            |
| 142      | NHC(O)O-(R,S)-2-pyranyl            |
| 143      | NHC(O)O-3-(N-tBOC)-piperidinyl     |
| 144      | NHC(O)O-(R)-3-(2-oxo-4,4-          |

- 26 -

| Compound | L   |
|----------|---|
| 145      | dimethyl) furanyl                             |
| 146      | NHC(O)O-3-methylthiopropyl                    |
| 147      | NHC(O)O-4-[(2,2-dimethyl)-1,3-dioxanyl]methyl |
| 148      | NHC(O)O-2-di-(hydroxymethyl)ethyl             |
| 149      | NHC(O)O-3-(N-tBOC)-piperidinylmethyl          |
| 150      | NHC(O)O-(dibenzylloxymethyl)methyl            |
| 151      | NHC(O)O-di-(hydroxymethyl)methyl              |
| 152      | NHC(O)O-2-(N-tBOC)-piperidinylmethyl          |
| 153      | NHC(O)O-3-piperidinyl-TFA                     |
| 154      | NHC(O)O-(R,S)-(2-tetrahydropyranyl)methyl     |
| 155      | NHC(O)O-4-piperidinylmethyl-TFA               |
| 156      | NHC(O)O-(R,S)-tetrahydrofuranyl methyl        |
| 157      | NHC(O)O-3-methylsulfonylpropyl                |
| 158      | NHC(O)O-3-piperidinylmethyl-TFA               |
| 159      | NHC(O)O-2-piperidinylmethyl-TFA               |
| 160      | NHC(O)O-(R,S)-3-tetrahydrothiophenyl          |
| 161      | NHC(O)O-(R,S)-3-tetrahydrothiopyranyl         |
| 162      | NHC(O)O-3-methoxypropyl                       |

5

Table IIIA




| #  | Q <sup>1</sup> | Q <sup>2</sup> | B                        |
|----|----------------|----------------|--------------------------|
| 28 | 3-methoxy      | 4-methoxy      | 3-methylphenyl           |
| 32 | 3-nitro        | H              | 3-methylphenyl           |
| 33 | 4-cyano        | H              | 3-methylphenyl           |
| 34 | 3-methoxy      | 4-methoxy      | 3-bromophenyl            |
| 35 | 3-methoxy      | 4-methoxy      | 2-methoxy-5-chlorophenyl |
| 36 | 3-methoxy      | 4-methoxy      | 3-fluorophenyl           |
| 37 | 3-methoxy      | 4-methoxy      | 3-ethylphenyl            |
| 38 | 3-methoxy      | 4-methoxy      | 3-methylthiophenyl       |
| 52 | 3-chloro       | 4-methoxy      | 3-nitrophenyl            |
| 70 | 4-cyano        | 3-chloro       | 3-methylphenyl           |
| 87 | 1-imidazolyl   | H              | 3-methylphenyl           |

- 27 -

|     |                              |           |                                    |
|-----|------------------------------|-----------|------------------------------------|
| 90  | 3-hydroxymethyl              | 4-methoxy | 3-methylphenyl                     |
| 103 | 3-(t-butoxycarbamoyl methyl) | H         | 3-(t-butoxycarbamoyl methyl)phenyl |

Table IIB



5

| #   | Q <sub>1</sub>        | Q <sub>3</sub>   |
|-----|-----------------------|--|
| 163 | Cl                    | N (Me) (Ac)  |
| 164 | OMe                   | N (Me) (Ac)  |
| 165 | SMe                   | CH <sub>2</sub> NHC (O) O- (3s) -<br>tetrahydrofuranyl |
| 166 | S (O) <sub>2</sub> Me | N (Me) (Ac)  |
| 167 | OMe                   | N (Me) (Ac)  |
| 168 | SMe                   | CH <sub>2</sub> NHC (O) O- (3s) -<br>tetrahydrofuranyl |

The compounds of Table IIA correspond to compounds of formula (II) wherein one of said B components is phenyl with two substituents, Q<sup>1</sup> and Q<sup>2</sup>.

10 In accordance with formula (II):

Q<sup>1</sup> is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>; and  
Q<sup>2</sup> is selected from R<sup>1</sup> or R<sup>4</sup>.

15 The compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration.

20 Combinations of substituents and variables envisioned by this invention are only those that result

- 28 -

in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a mammal or for use in affinity chromatography applications). Typically, such compounds are stable at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

As used herein, the compounds of this invention, including the compounds of formulae I-IX, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae I-IX.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include 5 acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, 10 hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, 15 phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in 20 obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and  $N-(C_{1-4} \text{ alkyl})_4^+$  salts. 25 This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

The compounds of this invention may be 30 synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials.


- 30 -

In general, compounds of formula (I)-(IX) are conveniently obtained via methods illustrated in General Synthetic Schemes 1-3.



5 In General Synthetic Scheme 1 (see below), an X-substituted aniline is reacted with a Y-substituted phenylisocyanate under standard conditions to give the desired urea. In this process, X and Y may be one or more independent substituents (or their suitably protected variants) as exemplified by the ring 10 substituents listed for compounds of formulae I-IX above, at any position on the aromatic ring.

- 31 -


General Synthetic Scheme 1:



General Synthetic Scheme 2:



General Synthetic Scheme 3:



- 32 -

In General Synthetic Scheme 2 (see above), a substituted benzaldehyde (here, 2-methoxy-4-nitro-substituted) is treated sequentially with tosylmethylisocyanide, to give the resulting oxazole, 5 then reduced by catalytic hydrogenation to give the desired aniline. Reaction of this aniline with an isocyanate (here, m-tolylisocyanate) under standard conditions gives the desired urea.

An alternate synthetic route is illustrated 10 in General Synthetic Scheme 3 (see above). A substituted benzaldehyde (here 4-nitro substituted) is converted to the corresponding oxazolyl aniline as shown in General Synthetic Scheme 2. This aniline is treated with a substituted benzoic acid (here, 3-methyl-substituted) and a carboxylic acid activating 15 agent, such as diphenylphosphoryl azide, under standard reaction conditions, to give the desired urea.

As can be appreciated by the skilled artisan, the above synthetic schemes are not intended to 20 comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the 25 various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds.

The compounds of this invention may be modified by appending appropriate functionalities to 30 enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability,

- 33 -

increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

5 The novel compounds of the present invention are excellent ligands for IMPDH. Accordingly, these compounds are capable of targeting and inhibiting IMPDH enzyme. Inhibition can be measured by various methods, including, for example, IMP dehydrogenase HPLC assays (measuring enzymatic production of XMP and NADH from 10 IMP and NAD) and IMP dehydrogenase spectrophotometric assays (measuring enzymatic production of NADH from NAD). [See C. Montero et al., Clinica Chimica Acta, 238, pp. 169-178 (1995)].

15 Pharmaceutical compositions of this invention comprise a compound of formulae (I), (II) or (VII) or a pharmaceutically acceptable salt thereof; an additional agent selected from an immunosuppressant, an anti-cancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-20 vascular hyperproliferation compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention comprise a compound of formulae (III)-(IX) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or 25 vehicle. Such composition may optionally comprise an additional agent selected from an immunosuppressant, an anti-cancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-30 vascular hyperproliferation compound.

The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a patient, together with a compound

of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

5                   Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug

10                  10 delivery systems (SEDDS) such as  $\alpha$ -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as

15                  15 phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts,

20                  20 colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such

25                  25 as  $\alpha$ -,  $\beta$ -, and  $\gamma$ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- $\beta$ -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of

30                  30 formulae I-IX.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally,

- 35 -

buccally, vaginally or via an implanted reservoir. We prefer oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, 5 intracutaneous, intravenous, intramuscular, intra-articular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection 10 or infusion techniques.

15 The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable 20 dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a 25 solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending 30 medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of

5 injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol  
10 diluent or dispersant such as those described in Pharmacopeia Helvetica, Ph. Helv., or a similar alcohol, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other  
15 dosage forms may also be used for the purposes of formulation.

20 The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral  
25 administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.  
30

The pharmaceutical compositions of this invention may also be administered in the form of

suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the 5 rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical 10 compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable 15 ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid 20 petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved 25 in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, 30 cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal 35 suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the IMPDH inhibitory compounds described herein are useful in a monotherapy and/or in combination therapy for the prevention and treatment of IMPDH mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.

When the compositions of this invention comprise a combination of an IMPDH inhibitor of formulae (I)-(IX) and one or more additional therapeutic or prophylactic agents, both the IMPDH inhibitor and the additional agent should be present at age levels of between about 10 to 100%, and more

- 39 -

preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of 5 this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

According to one embodiment, the pharmaceutical compositions of this invention comprise 10 an additional immunosuppression agent. Examples of additional immunosuppression agents include, but are not limited to, cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin; prednisone, azathioprine, mycophenolate mofetil, OKT3, ATAG, interferon and 15 mizoribine.

According to an alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise an anti-cancer agent. Examples of anti-cancer agents include, but are not limited to, 20 cis-platin, actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipaside, taxol, colchicine, cyclosporin A, phenothiazines, interferon and thioxantheres.

According to another alternate embodiment, 25 the pharmaceutical compositions of this invention may additionally comprise an anti-viral agent. Examples of anti-viral agents include, but are not limited to, Cytovene, Ganciclovir, trisodium phosphonoformate, Ribavirin, d4T, ddI, AZT, and acyclovir.

According to yet another alternate 30 embodiment, the pharmaceutical compositions of this invention may additionally comprise an anti-vascular hyperproliferative agent. Examples of anti-vascular

- 40 -

hyperproliferative agents include, but are not limited to, HMG Co-A reductase inhibitors such as lovastatin, thromboxane A2 synthetase inhibitors, eicosapentanoic acid, ciprostone, trapidil, ACE inhibitors, low 5 molecular weight heparin, mycophenolic acid, rapamycin and 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if 10 necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should 15 cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

As the skilled artisan will appreciate, lower or higher doses than those recited above may be 20 required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of 25 excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician.

In an alternate embodiment, this invention provides methods of treating or preventing IMPDH 30 mediated disease in a mammal comprising the step of administrating to said mammal any of the pharmaceutical compositions and combinations described above. If the pharmaceutical composition only comprises the IMPDH

inhibitor of this invention as the active component, such methods may additionally comprise the step of administering to said mammal an agent selected from an antiinflammatory agent, immunosuppressant, an anti-  
5 cancer agent, an anti-viral agent, or an anti-vascular hyperproliferation compound. Such additional agent may be administered to the mammal prior to, concurrently with, or following the administration of the IMPDH inhibitor composition.

10 In a preferred embodiment, these methods are useful in suppressing an immune response in a mammal. Such methods are useful in treating or preventing diseases, including, transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells),  
15 bone marrow, cornea, small bowel and skin allografts and heart valve xenografts), graft versus host disease, and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitis), lupus, diabetes, mellitus myasthenia gravis, psoriasis, dermatitis, eczema, seborrhoea, pulmonary inflammation, eye uveitis, hepatitis, Grave's disease, Hashimoto's thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes/mouth), pernicious or immunohaemolytic  
20 anaemia, idiopathic adrenal insufficiency, polyglandular autoimmune syndrome, glomerulonephritis, scleroderma, lichen planus, viteligo (depigmentation of the skin), autoimmune thyroiditis, and alveolitis.  
25

These methods comprise the step of  
30 administering to the mammal a composition comprising a compound of any of formulae I-IX and a pharmaceutically acceptable adjuvant. In a preferred embodiment, this particular method comprises the additional step of

- 42 -

administering to said mammal a composition comprising an additional immunosuppressant and a pharmaceutically acceptable adjuvant.

5 Alternatively, this method comprises the step of administering to said mammal a composition comprising a compound of formulae I-IX; an additional immunosuppressive agent and a pharmaceutically acceptable adjuvant.

10 In an alternate preferred embodiment, these methods are useful for inhibiting viral replication in a mammal. Such methods are useful in treating or preventing, DNA and RNA viral diseases caused by, for example, HTLV-1 and HTLV-2, HIV-1 and HIV-2, nasopharyngeal carcinoma virus, HBV, HCV, HGV, yellow 15 fever virus, dengue fever virus, Japanese encephalitis virus, human papilloma virus, rhinoviruses and Herpes viruses, such as Epstein-Barr, cytomegaloviruses and Herpes Simplex, Types 1 and 2, or Type 6. [See, United States patent 5,380,879].

20 These methods comprise the step of administering to the mammal a composition comprising a compound of any of formulae I-IX, and a pharmaceutically acceptable adjuvant. In a preferred embodiment, this particular method comprises the 25 additional step of administering to said mammal a composition comprising an additional anti-viral agent and a pharmaceutically acceptable adjuvant.

30 Alternatively, this method comprises the step of administering to said mammal a composition comprising a compound of formulae I-IX; an additional anti-viral agent and a pharmaceutically acceptable adjuvant.

- 43 -

In another alternate preferred embodiment, these methods are useful for inhibiting vascular cellular hyperproliferation in a mammal. Such methods are useful in treating or preventing diseases, 5 including, restenosis, stenosis, atherosclerosis and other hyperproliferative vascular disease.

These methods comprise the step of administering to the mammal a composition comprising a compound of any of formulae I-IX, and a 10 pharmaceutically acceptable adjuvant. In a preferred embodiment, this particular method comprises the additional step of administering to said mammal a composition comprising an additional anti-vascular hyperproliferative agent and a pharmaceutically 15 acceptable adjuvant.

Alternatively, this method comprises the step of administering to said mammal a composition comprising a compound of formulae I-IX; an additional anti-vascular hyperproliferative agent and a 20 pharmaceutically acceptable adjuvant.

In another alternate preferred embodiment, these methods are useful for inhibiting tumors and cancer in a mammal. Such methods are useful in treating or preventing diseases, including, tumors and 25 malignancies, such as lymphoma, leukemia and other forms of cancer.

These methods comprise the step of administering to the mammal a composition comprising a compound of any of formulae I-IX, and a 30 pharmaceutically acceptable adjuvant. In a preferred embodiment, this particular method comprises the additional step of administering to said mammal a composition comprising an additional anti-tumor or

- 44 -

anti-cancer agent and a pharmaceutically acceptable adjuvant.

Alternatively, this method comprises the step of administering to said mammal a composition comprising a compound of formulae I-IX; an additional anti-tumor or anti-cancer agent and a pharmaceutically acceptable adjuvant.

In another alternate preferred embodiment, these methods are useful for inhibiting inflammation and inflammatory diseases in a mammal. Such methods are useful in treating or preventing diseases, including, osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma and adult respiratory distress syndrome.

These methods comprise the step of administering to the mammal a composition comprising a compound of any of formulae I-IX, and a pharmaceutically acceptable adjuvant. In a preferred embodiment, this particular method comprises the additional step of administering to said mammal a composition comprising an antiinflammatory agent and a pharmaceutically acceptable adjuvant.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

#### General Materials and Methods

All temperatures are recorded in degrees Celsius. Thin layer chromatography (TLC) was carried out using 0.25 mm thick E. Merck silica gel 60 F<sub>254</sub> plates and elution with the indicated solvent system.

- 45 -

Detection of the compounds was carried out by treating the plate with an appropriate visualizing agent, such as 10% solution of phosphomolybdic acid in ethanol or a 0.1% solution of ninhydrin in ethanol, followed by 5 heating, and/or by exposure to UV light or iodine vapors when appropriate. Analytical HPLC was carried out using a Rainin Mycrosorb-MV, 5 $\mu$  Cyano reverse phase column, 3.9mm x 150mm, with a flow rate of 1.0mL/minute and a solvent gradient of 5-100% acetonitrile (0.1% 10 TFA) in water (0.1% TFA). HPLC retention times were recorded in minutes. NMR spectral data was acquired using a Bruker AMX500 in the indicated solvent.

The IMP dehydrogenase HPLC assay follows our standard conditions for the enzymatic production of XMP and NADH from IMP and NAD, but utilizes high pressure liquid chromatography on a C18 column with ion pairing reagents to separate all four components. The extent of reaction is then determined from the resulting product peak areas. This assay is particularly useful 15 for determining the inhibition profiles of compounds 20 which have significant absorbance in the UV-visible region between 290 and 340 nM.

The reaction mixture typically contains 0.1 M KPi; pH 8.0, 0.1M KCl, 0.5 mM EDTA, 2 mM DTT, and 0.2 mM each of IMP and NAD. This solution is incubated at 25 37°C for 10 minutes. The reaction is started by the addition of enzyme to a final concentration of 20 to 100 nM, and is allowed to proceed for 10 minutes. After the allotted time, the reaction is quenched by 30 the addition of mycophenolic acid to a final concentration of 0.01 mM.

The extent of conversion is monitored by HPLC using a Rainin Microsorb ODS column C18-200 of

dimensions 4.6 X 10 mm and a solvent system containing tetrabutylammonium sulfate (5mM) in 0.1 M KPi pH 6.0 with a 0-30% methanol gradient over 15 minutes. A similar solvent system has been used previously for the purification of halo-IMP derivatives. [L. C. Antionio and J. C. Wu, Biochemistry, 33, 1753-1759 (1994).] A UV-monitor set at 254 nM is used to detect the four components, and the product peaks are integrated to determine the extent of conversion of the substrates.

For the analysis of inhibitors, the compound in question is dissolved in DMSO to a final concentration of 20 mM and added to the initial assay mixture at the desired concentration in a volume of 2-5% (v/v). The reaction is started by the addition of enzyme and after 10 minutes is quenched as above. After HPLC analysis, the product areas are used to determine the extent of conversion relative to a control assay containing only DMSO and no test compound. IC<sub>50</sub> or Ki values are determined from non linear least squares fitting of conversion vs concentration curves to the tight-binding equations of Henderson. [P. J. F. Henderson, Biochem. J., 127, 321 (1972).]

We have measured the inhibition constants of each compound against IMPDH using an adaptation of the method first reported by Magasanik. [B. Magasanik, H. S. Moyed, and L. B. Gehring J. Biol. Chem., 226, p.339 (1957)].


Insofar as compounds of formulae I-IX are able to inhibit IMPDH, they are of evident clinical utility for the treatment of IMPDH mediated disease. These tests are predictive of the compounds ability to inhibit IMPDH in vivo.

- 47 -

Experimental Section

## Synthesis of Representative Examples:


5

Example 1  
Synthesis of Compound 1

(1)


10 To a solution of 25mg (156 $\mu$ mole) 4-(5-oxazolyl)-aniline in 250 $\mu$ L CH<sub>2</sub>Cl<sub>2</sub> was added 50 $\mu$ L (400  $\mu$ mole) of benzyl isocyanate at ambient temperature. After stirring overnight, 1 was isolated in pure form by filtration with a 3:1 hexanes/CH<sub>2</sub>Cl<sub>2</sub> rinse in a 15 yield of 21mg (46%). <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>)  $\delta$  7.86(s), 7.55(d), 7.38(d), 7.22-7.35(m), 6.39(s), 5.0(br s), 4.43(s). R<sub>f</sub> 0.30 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

20

Example 2  
Synthesis of Compound 43

B1

To a solution of glacial acetic acid (46mL), acetic anhydride (46mL, 485mmole) and 2-chloro-4-nitrotoluene (5g, 29.1mmole) at 0 °C was added conc. 5  $H_2SO_4$  (6.9mL) in a dropwise fashion. Upon complete addition,  $CrO_3$  (8.08g, 80.8mmole) was added portionwise over 60 mins. Following an additional 15 mins of stirring at 0 °C, the reaction mixture was poured over ice and the resulting precipitate was isolated by 10 filtration, rinsing with cold  $H_2O$ . Purification by flash chromatography, eluting with a gradient of 15-50% EtOAc in hexanes, provided 2.02g (24%, 40% based on recovered starting material) **B1** as a white solid. The  $^1H$  NMR was consistent with that of the desired 15 structure.




**B2**

Compound **B1** was dissolved in 1:1 20 ethanol/water (20mL), treated with conc.  $H_2SO_4$  (2mL) and refluxed for 1 hour. Upon cooling to ambient temperature, the reaction was extracted 3x's with diethyl ether. The ethereal solution was washed twice with water, dried over  $Na_2SO_4$  and concentrated in vacuo 25 to yield a yellow solid. Purified product was obtained through two recrystallizations from hot  $Et_2O$ /hexanes, yielding 620mg (47.6%) **B2** as a lightly yellowed

- 49 -

crystalline solid. The  $^1\text{H}$  NMR was consistent with that of the desired structure.



B3


5

A mixture of **B2** (200mg, 1.2mmol), tosylmethyl isocyanide (236mg, 1.2mmol), and powdered  $\text{K}_2\text{CO}_3$  (172mg, 1.2mmole) in methanol (13mL) was heated at reflux for 90 minutes and then stirred overnight at ambient temperature. Upon concentration to dryness, the mixture was partitioned between  $\text{CH}_2\text{Cl}_2$  and water. The organics were separated, washed with 0.5N HCl, water and brine and then dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed *in vacuo* to provide a crude yellow solid. Purified product **B3** was obtained through flash chromatography, eluting with a gradient of 0-2.5%  $\text{CH}_3\text{OH}$  in  $\text{CH}_2\text{Cl}_2$ , and recrystallization ( $\text{CH}_2\text{Cl}_2$ /hexanes) in a yield of 3.3g (68%) as a light yellow crystalline solid. The  $^1\text{H}$  NMR was consistent with that of the desired structure.

10

15

20



B4

25


25

A solution of **B3** (150mg, 0.67mmole) in

ethanol (7.5mL) was treated with  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (excess;

ca. 5 equivalents) and heated at reflux for 30 minutes. The mixture was cooled to ambient temperature, diluted with diethyl ether and partitioned with 2N NaOH. The organics were separated, washed with water and brine, 5 dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. Purified product **B4** was obtained through flash chromatography, eluting with a gradient of 0-0.5% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>, in a yield of 54mg (41.5%) as a light yellow oil. The <sup>1</sup>H NMR was consistent with that of the desired structure.

10




(43)

To a solution of 20mg (103 $\mu$ mole) **B4** in 1mL 15 CH<sub>2</sub>Cl<sub>2</sub> was added 20 $\mu$ L *m*-tolylisocyanate at ambient temperature. After stirring overnight, **43** was isolated in pure form by filtration with an EtOAc/hexanes rinse in a yield of 25mg (74%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO)  $\delta$  20 9.06 (s), 8.73 (s), 8.50 (s), 7.89 (s), 7.73 (d), 7.67 (s), 7.42 (d), 7.31 (s), 7.23 (d), 7.18 (t), 6.82 (d), 2.27 (s). R<sub>f</sub> 0.28 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

- 51 -


Example 3  
Synthesis of Compound 56



5

C1

C1 (8.14g, 51%) was prepared from 2-methyl-5-nitroanisole (10.0g, 60mmole) in a fashion directly analogous to the preparation of B1 as described above. The <sup>1</sup>H NMR was consistent with that of the desired structure.




15

C2

A stirred suspension of C1 (81.94g, 307mmole) in dioxane (100mL) was treated with concentrated HCl (20mL) and heated at reflux overnight. Upon cooling to ambient temperature, the product C2 precipitated as a light yellow crystalline solid in a yield of 40.65g (73.1%). The filtrate was concentrated to a volume of ca. 80mL and a second crop of product crystals was driven from solution by the addition of hexanes, yielding 8.91g (16.0%). Both batches were identical by <sup>1</sup>H NMR and TLC analysis and were consistent with that

- 52 -

of the desired material. The total yield of **C2** was 49.56g (89.1%).




5

**C3**

10 A solution of **C2** (456mg, 2.51mmole), tosylmethyl isocyanide (490mg, 2.51mmole) and  $K_2CO_3$  (347mg, 251mmole) were dissolved in methanol and heated to reflux for 1.5 hours. The product mixture was then concentrated *in vacuo*, redissolved in  $CH_2Cl_2$ , washed with water and brine, dried over  $Na_2SO_4$  and again concentrated *in vacuo*. Purified product **C3** was obtained through recrystallization ( $Et_2O$ /hexanes) to

15 yield 375mg (68%). The  $^1H$  NMR was consistent with that of the desired structure.



20

**C4**


25

A solution of **C3** (4.214g, 19.1mmole) in  $EtOAc$  (150mL) was treated with 10%Pd/C (1.05g, 25 wt.% of **C3**) and subjected to 40psi  $H_2(g)$  (Parr Hydrogenation Apparatus) overnight. The reaction mixture was filtered and concentrated *in vacuo*. Pure product **C4**

- 53 -

was obtained through flash chromatography, eluting with a gradient of 30-40% EtOAc/hexanes, in a yield of 3.4g (93%). The <sup>1</sup>H NMR was consistent with that of the desired structure.

5




(56)

To a solution of **C4** (25mg, 0.131mmole) in CH<sub>2</sub>Cl<sub>2</sub> (1mL) was added toll isocyanate (25μL, 0.197mmole) at ambient temperature. After stirring overnight, **56** was isolated in pure form by filtration with a CH<sub>2</sub>Cl<sub>2</sub> rinse in a yield of 42mg (74%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 8.87 (s), 8.64 (s), 8.37 (s), 7.60 (d), 7.46 (d), 7.42 (s), 7.33 (s), 7.23 (d), 7.16-7.19 (t), 7.05 (dd), 6.80 (d), 3.92 (s), 2.28 (s). R<sub>f</sub> 0.46 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

- 54 -

Example 4  
Synthesis of Compound 59




5

D1

To a solution of C4 (75mg, 0.394mmole) in dichloroethane (5mL) was added 3-nitrophenyl isocyanate (97mg, 0.591mmole) at ambient temperature. After 10 stirring overnight, D1 was isolated in pure form by filtration with a  $\text{CH}_2\text{Cl}_2$  rinse in a yield of 110.3mg (79%). The  $^1\text{H}$  NMR was consistent with that of the desired structure.

15



(59)

To a stirred suspension of D1 (95mg, 0.268mmole) in EtOH (20mL) was added  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (302mg, 1.34mmole). The reaction mixture was brought to 20 reflux, at which time dissolution occurred, for 1.5 hours. The solution was cooled to ambient temperature, diluted with EtOAc, washed with 2N NaOH and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo*. Pure product


- 55 -

59 was obtained through flash chromatography (eluting with a gradient of 2.5-5% MeOH in  $\text{CH}_2\text{Cl}_2$ ), followed by selective crystallization of the desired material from slightly impure fractions in a yield of 15.7mg (18%).

5  $^1\text{H}$  NMR (500MHz,  $d_6$ -DMSO)  $\delta$  8.83 (s), 8.44 (s), 8.35 (s), 7.59 (d), 7.48 (d), 7.40 (s), 6.97-7.04 (dd), 6.86-6.92 (t), 6.83 (d), 6.54 (dd), 6.20 (dd), 5.05 (br s), 3.92 (s).  $R_f$  0.20 (5% MeOH/ $\text{CH}_2\text{Cl}_2$ ).

10


Example 5  
Synthesis of Compound 113



E1

15

A solution of 3-aminobenzylamine (826mg, 6.87mmole) and triethylamine (2.39mL, 17.18mmole) was treated with di-*t*-butyldicarbonate (1.50g, 6.87mmole) and the mixture was stirred at ambient temperature for 20 2 hours. The reaction was then diluted with  $\text{CH}_2\text{Cl}_2$ , washed with  $\text{NaHCO}_3$  (aq), water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo*. Pure E1 was obtained by flash chromatography, eluting with 25% EtOAc in hexanes in a yield of 200mg (46%). The  $^1\text{H}$  NMR was consistent 25 with that of the desired structure.




(113)

A solution of **C4** (150mg, 0.789mmole) and 1,1-dicarbonylimidiazole (160mg, 0.986mmole) were combined in THF (5mL) and stirred for 6 hours at ambient temperature. The precipitation of imidazole was noted. To this was then added **E1** (351mg, 1.58mmole) and *N,N*-dimethylaminopyridine (97mg, 0.789mmole) and the mixture was refluxed overnight, resulting in a homogenous solution. Upon cooling to ambient temperature, the reaction was diluted with EtOAc (20mL), washed with KHSO<sub>4</sub> (aq), water, and brine, dried (MgSO<sub>4</sub>) and concentrated. Pure **113** was obtained through flash chromatography, eluting with a gradient of 20-30-35% acetone in hexanes in a yield of 164mg (47%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 8.90 (s), 8.75 (s), 8.38 (s), 7.60 (d), 7.51 (s), 7.3-7.46 (m), 7.21-7.27 (t), 7.05 (dd), 6.87 (d), 4.12 (d), 3.93 (s), 1.44 (s). R<sub>f</sub> 0.21 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

- 57 -

Example 6

Synthesis of Compound 70



(70)


5

A solution of 3-chloro-4-cyanoaniline (500mg, 7.76mmole) and *m*-tolylisocyanate (1.0mL, 3.17mmole) in CH<sub>2</sub>Cl<sub>2</sub> (3mL) was stirred overnight at ambient temperature. The reaction mixture was concentrated and pure 70 was obtained through MPLC, eluting with 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, in a yield of 285mg (31%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 9.36 (s), 8.88 (s), 7.94 (s), 7.83 (d), 7.44 (d), 7.30 (s), 7.24 (d), 7.15-7.20 (t), 6.82 (d), 2.29 (s). R<sub>f</sub> 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

15

Example 7

Synthesis of Compound 108




G1

20

To a solution of 3,4,5-trimethoxyacetophenone (9.2g, 43.4 mmol) in pyridine (35mL) was added selenium dioxide (6.3g, 56.7mmol) and the resulting solution was heated at reflux overnight. The reaction mixture was cooled to ambient temperature, filtered through celite

and concentrated to yield a dark brown oil which was dissolved into ethyl acetate and washed with 1.0 N HCl and then with saturated NaHCO<sub>3</sub>. The basic aqueous layer was diluted with ether and acidified with 5 concentrated HCl. The layers were separated and the organic phase was washed with brine and then dried (Na<sub>2</sub>SO<sub>4</sub>) to give 8.4 g of a dark yellow solid. Recrystallization of this material from ethyl acetate-hexane then gave **G1** (6.8 g) as a pale yellow solid. 10 The <sup>1</sup>H NMR was consistent with that of the desired structure.



(108)


15

A mixture of **59** (64mg, 0.20mmole), **G1** (300mg, 1.20mmole) and EDC (300mg, 1.6mmole) in THF (5mL) was stirred overnight at ambient temperature. The reaction was diluted with EtOAc (150mL), washed with water, 20 dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. Pure **108** was obtained through MPLC, eluting with a gradient system of 0-1%MeOH in CH<sub>2</sub>Cl<sub>2</sub>, in a yield of 37.4mg (35%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 9.83 (s), 8.23 (s), 8.18 (s), 7.65 (s), 7.61 (s), 7.35 (d), 7.33 (s), 7.29 (s), 25 7.27 (s), 7.11 (s), 7.06-7.10 (t), 6.94-6.99 (t), 6.52 (d) 3.68 (s), 3.63 (s), 3.61 (s). R<sub>f</sub> 0.26 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

- 59 -

Example 8

## Synthesis of Compound 115



5


(115)

A solution of 59 (300mg, 1.58mmole) and *m*-toll isothiocyanate (2.0mL, 14.7mmole) in CH<sub>2</sub>Cl<sub>2</sub> (5mL) was stirred at ambient temperature overnight. To drive 10 the reaction to completion, additional *m*-toll isothiocyanate (1.0mL, 7.4mmole) was added and the mixture was heated to reflux for 3 hours. The reaction was concentrated *in vacuo* and 115 was obtained in pure form through MPLC, eluting with 0-5% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>, 15 in a yield of 210mg (39%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 7.90 (s), 7.89 (s), 7.82 (s), 7.75 (d), 7.64 (s) 7.44 (s), 7.32-7.37 (t), 7.27 (s), 7.13-7.21 (m), 6.91 (dd), 3.98 (s), 2.40 (s). R<sub>f</sub> 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

20

Example 9

## Synthesis of Compound 97




II

25

A solution of nitroaniline (1.0g, 7.13mmole) in CH<sub>2</sub>Cl<sub>2</sub> (25mL) was treated with pyridine (2.9mL,

- 60 -


36mmole) and trifluoroacetic anhydride (5mL, 36mmole) and stirred at ambient temperature for 3 hours. The reaction was diluted further with  $\text{CH}_2\text{Cl}_2$ , washed with 1N HCl and brine, dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to yield **I1** (1.61g, 95%) as a white solid. The  $^1\text{H}$  NMR was consistent with that of the desired structure.



**I2**

10

To a slurry of NaH (60% oil dispersion; 34 mg, 1.42mmole) in THF (10mL) at 0 °C was added a solution of **I1** (200mg, 0.85mmole) in THF (10mL) and the mixture stirred for 1 hour. To this was added methyl iodide (100 $\mu$ L, 1.7mmole) and the mixture was stirred overnight at ambient temperature. The reaction was poured into water and extracted with EtOAc. The organics were separated, dried ( $\text{MgSO}_4$ ) and concentrated in vacuo. Pure **I2** was obtained through flash chromatography, eluting with 5% EtOAc in hexanes, in a yield of 163mg (66%) as a yellow solid. The  $^1\text{H}$  NMR was consistent with that of the desired structure.



**I3**


25

A solution of **I2** (163mg, 0.66mmole) in ethanol (5mL) was treated with Pd/C (20mg) and

- 61 -

subjected to H<sub>2</sub> (1 atm.) for 3 hours. The reaction was filtered and concentrated *in vacuo* to yield I3 (120mg, 84%) as a waxy solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.

5




(97)

To a solution of triphosgene (31mg, 0.104mmole) in dichloroethane (1mL) was added in a dropwise fashion a solution of B4 (50mg, 0.260mmole) and diisopropylethylamine (67mg, 518mmole) in dichloroethane (5mL). The reaction mixture was stirred for an additional 1 hour at ambient temperature, treated with I3 (50mg, 0.230 mmole) and stirred overnight. The entire reaction mixture was subjected to flash chromatography, eluting with 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, to provide pure 97 in a yield of 8mg (7%). <sup>1</sup>H NMR (500MHz, d<sub>6</sub>-DMSO) δ 9.20 (s), 8.98 (s), 8.39 (s), 7.67 (s), 7.63 (d), 7.48 (s), 7.38-7.45 (m), 7.04-7.10 (t), 3.95 (s), 3.31 (s). R<sub>f</sub> 0.37 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>).

- 62 -

Example 10  
Synthesis of Compound 111



(111)

5


A solution of 59 (50mg, 0.154mmole) and triethylamine (31mg, 0.308mmole) in DMF (0.5mL) was treated in a dropwise fashion with phenylacetyl chloride (25mg, 0.169mmole) and the reaction stirred overnight at ambient temperature. The mixture was diluted with  $\text{CH}_2\text{Cl}_2$ , washed with  $\text{NaHCO}_3$  (aq) and water, dried over  $\text{MgSO}_4$  and concentrated *in vacuo*. Pure 111 was isolated by flash chromatography, eluting with 2% MeOH in  $\text{CH}_2\text{Cl}_2$ , in a yield of 42mg (62%).  $^1\text{H}$  NMR (500MHz,  $d_6$ -DMSO)  $\delta$  10.20 (s), 8.90 (s), 8.79 (s), 8.39 (s), 7.88 (s), 7.63 (d), 7.53 (d), 7.44 (s), 7.25-7.40 (m), 7.22 (t), 7.14 (d), 7.05 (dd), 3.96 (s), 3.66 (s).  $R_f$  0.31 (5% MeOH/ $\text{CH}_2\text{Cl}_2$ ).

15

(500MHz,  $d_6$ -DMSO)  $\delta$  10.20 (s), 8.90 (s), 8.79 (s), 8.39 (s), 7.88 (s), 7.63 (d), 7.53 (d), 7.44 (s), 7.25-7.40 (m), 7.22 (t), 7.14 (d), 7.05 (dd), 3.96 (s), 3.66 (s).  $R_f$  0.31 (5% MeOH/ $\text{CH}_2\text{Cl}_2$ ).

20

Example 11  
Synthesis of Compound 102




K1

A solution of 2-methyl-5-nitrobenzoic acid (15g, 82.8mmole) in DMF (75mL) was treated with methyl

- 63 -

iodide (6.7mL, 107.64mmole) followed by powdered  $K_2CO_3$  (17.2g, 124.2mmole) (extreme exotherm) and the suspension stirred at ambient temperature overnight. The reaction mixture was partitioned between EtOAc and water, the organics separated and washed with water and brine, dried ( $Na_2SO_4$ ) and concentrated in vacuo to yield **K1** (15.86g, 98%) in pure form as an off-white solid. The  $^1H$  NMR was consistent with that of the desired structure.


10



**K2**

15 **K2** (4.09g, 16.2%) was prepared from **K1** (15.86g, 81.3mmole) in a fashion analogous to the preparation of **B1** as described above. The  $^1H$  NMR was consistent with that of the desired structure.

20




**K3**

A solution of **K2** (2.5g, 8.03mmole) in dioxane (10mL) was treated with conc. HCl (0.5mL) and the mixture was heated to reflux for 2 hours. Additional conc. HCl (0.5mL) was added and the reaction refluxed for 3 hours longer. The mixture was diluted with EtOAc, washed with water and brine, dried ( $Na_2SO_4$ ) and concentrated in vacuo. Pure **K3** was obtained through


- 64 -

flash chromatography, eluting with a gradient of 20-30-50% Et<sub>2</sub>O in hexanes, in a yield of 1.14g (68%). Also isolated was 215mg (11.8%) of the hydrated aldehyde. The <sup>1</sup>H NMRs were consistent with that of the desired structures.



K4


A solution of K3 (300mg, 1.43mmole) in benzene (5mL) was treated with 1,3-propane diol (114 $\mu$ L, 1.573mmole) and *p*-TsoH $\cdot$ H<sub>2</sub>O (27mg, 0.14mmole) and the mixture was refluxed with Dean-Stark removal of water for 4.5 hours. The reaction was cooled to ambient temperature, partitioned between EtOAc and dilute NaHCO<sub>3</sub>, the organics separated, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo*. Pure K4 was obtained through flash chromatography, eluting with a gradient of 20-25% Et<sub>2</sub>O in hexanes, in a yield of 324mg (84.5%) as an off-white crystalline solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.



K5

- 65 -


A solution of **K4** (289mg, 1.08mmole) in THF (5mL) at 0 °C was treated dropwise with a solution of DIBAL (1.0M in CH<sub>2</sub>Cl<sub>2</sub>; 2.7mL, 2.7mmole) and stirred 5 for 40 minutes. The reaction was quenched by addition of saturated Rochelle's salt solution (10mL), diluted with EtOAc and stirred for 30 minutes. The organics were collected, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo* to give 250mg (97%) of **K5** as a 10 white crystalline solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.



**K6**


15 A solution of **K5** (250mg, 1.05mmole) in CH<sub>2</sub>Cl<sub>2</sub> (4mL) at 0 °C was treated with pyridine (110µL, 1.37mmole), benzoyl chloride (146µL, 1.26mmole) and 4-DMAP (catalytic), and stirred at ambient temperature overnight. The reaction mixture was diluted with 20 CH<sub>2</sub>Cl<sub>2</sub>, washed with 0.5N HCl, water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo*. Pure **K6** was obtained through flash chromatography, eluting with 10% EtOAc in hexanes, in a yield of 340mg (99%) as a white 25 solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.

- 66 -



K7

5 A solution of **K6** (326mg, 0.99mmole) in dioxane (7mL) was treated with 2.0N HCl (5mL) and the mixture heated at 80 °C overnight. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO<sub>3</sub>(aq), water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo*. Pure **K7** was obtained through 10 flash chromatography, eluting with 30% Et<sub>2</sub>O in hexanes, in a yield of 208mg (77.5%) as a white solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.



15


K8

20 A solution of **K7** (208mg, 0.729mmole) in MeOH (6mL) was treated with K<sub>2</sub>CO<sub>3</sub> (101mg, 0.765mmole) and TosMIC (149mg, 0.765mmole) and the solution heated at 60 °C for one hour. The reaction was concentrated *in vacuo*, redissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with 1.0N NaOH (diluted with saturated NaHCO<sub>3</sub>). The aqueous portion was back-extracted with CH<sub>2</sub>Cl<sub>2</sub>, the organics combined and washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and

- 67 -

concentrated *in vacuo*. Pure **K8** was obtained through flash chromatography, eluting with a gradient of 10-50% acetone in hexanes, in a yield of 70mg (44%). The <sup>1</sup>H NMR was consistent with that of the desired structure.

5




**K9**

10 A solution of **K8** (70mg, 0.318) in acetic anhydride (1.5mL) and pyridine (1.0mL) was treated with 4-DMAP (catalytic) and stirred at ambient temperature for 3 hours. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with 1.0N HCl, water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo* to provide **K9** in a yield of 82mg (98%) as a pale yellow solid. The <sup>1</sup>H NMR was consistent with that of the desired structure.

15

20




**K10**

20 A solution of **K9** (80mg, 0.305mmole) in dry EtOH (4mL) was treated with SnCl<sub>2</sub>•2H<sub>2</sub>O (241mg,

- 68 -


1.07mmole) and the mixture heated at 60 °C for 50 minutes. The reaction was diluted with EtOAc, washed with saturated NaHCO<sub>3</sub>, water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo*. Pure **K10** was obtained through flash chromatography, eluting with a gradient of 20-30% acetone in hexanes, in a yield of 52mg (73.4%) as a pale yellow oil. The <sup>1</sup>H NMR was consistent with that of the desired structure.



10

K11

A solution of **K10** (52mg, 0.224mmole) in dichloroethane (2mL) was treated with *m*-tolyl isocyanate (43 $\mu$ L, 0.336mmole) and stirred overnight at ambient temperature. The mixture was diluted with  $\text{CH}_2\text{Cl}_2$ :hexanes (2:1), filtered and rinsed with the same solvent system to provide **K11** (67mg, 82%) as a white solid. The  $^1\text{H}$  NMR was consistent with that of the desired structure.



20

(102)


- 69 -

A solution of **K11** (33mg, 0.09mmole) in MeOH (2mL) was treated with 1.0N NaOH (135  $\mu$ L, 0.135mmole) and stirred at ambient temperature for 1.5 hours. The reaction was neutralized by addition of 1.0N HCl (135  $\mu$ L) and concentrated *in vacuo*. The white solid was rinsed with water and  $\text{CH}_2\text{Cl}_2$ :hexanes (2:1) and dried *in vacuo* to provide **102** (20mg, 68%) as a white solid.  $^1\text{H}$  NMR (500MHz,  $d_6$ -DMSO)  $\delta$  9.29 (s), 9.00 (s), 8.42 (s), 7.69 (s), 7.55 (m), 7.37 (s), 7.33 (s), 7.27 (d), 7.16 (t), 6.80 (d), 5.39 (t), 4.58 (s), 2.28 (s).  $R_f$  0.13 (1:1 hexanes/acetone).

Example 12

Synthesis of Compound 106

15




(106)

A solution of **C4** (50mg, 0.263mmole) in THF (2mL) was treated with CDI (53mg, 0.330mmole) and stirred at ambient temperature for 4 hours. To this was added 1-acetyl-6-aminoindole (93mg, 0.526mmole, Sigma Chemical Co.) and 4-DMAP (35mg, 0.289mmole) and the mixture refluxed overnight. Diluted with EtOAc (100mL), washed with 5%  $\text{KHSO}_4$ , water and brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo*. Redissolved in EtOAc and filtered to removed insoluble materials and

- 70 -

reconcentrated *in vacuo*. Pure **106** was obtained through flash chromatography, eluting with a gradient of 50-60% acetone in hexanes, in a yield of 37mg (36%) as a white solid.  $^1\text{H}$  NMR (500MHz,  $\text{d}_6\text{-DMSO}$ )  $\delta$  8.79 (s), 8.74 (s), 8.37 (s), 8.11 (s), 7.62 (d), 7.47 (s), 7.43 (s), 7.30 (d), 7.13 (d), 7.14 (d), 4.11 (t), 3.94 (s), 3.07 (t), 2.17 (s).  $R_f$  0.14 (1:1 hexanes/acetone).

Example 13




10

**(168)**

A suspension of **113** (from Example 5) (250mg, 5.76mmol) in  $\text{CH}_2\text{Cl}_2$  (1mL) was treated in a dropwise fashion at ambient temperature with several equivalents of trifluoroacetic acid and stirred for 90min. The resulting solution was stripped *in vacuo* and triturated with  $\text{CH}_2\text{Cl}_2$  and methanol. Pure product **168** was isolated by filtration in a yield of 258mg (99%). The  $^1\text{H}$  NMR was consistent with that of the desired product.

20



**(120)**

A suspension of **168** (250mg, 0.55mmol) in 21mL of  $\text{CH}_2\text{Cl}_2$ /DMF (20:1 by volume) was treated with triethyl

- 71 -

amine (193 $\mu$ L, 1.38mmol) and stirred at ambient temperature until homogeneity was reached. The solution was cooled to 0 C, treated with (S) 3-tetrahydrofuryl-N-oxysuccinimidyl carbonate (635mg, 0.608mmol) and allowed to stir overnight with warming to ambient temperature. The mixture was poured into ethyl acetate (500mL), washed with NaHCO<sub>3</sub>(aq) (2x), water (2x), and brine(1x), dried over Na<sub>2</sub>SO<sub>4</sub> and stripped *in vacuo*. Pure product 120 was isolated by 10 tritration (30mL CH<sub>2</sub>Cl<sub>2</sub>, 100mL ether) in a yield of 212mg (85%). The <sup>1</sup>H NMR was consistent with that of the desired product.

15

#### Example 14

##### IMPDH Activity Inhibition Assay

20 We measured the inhibition constants of the compounds listed in Table III utilizing the following protocol:

25 IMP dehydrogenase activity was assayed following an adaptation of the method first reported by Magasanik. [Magasanik, B. Moyed, H. S. and Gehring L. B. (1957) J. Biol. Chem. 226, 339]. Enzyme activity was measured spectrophotometrically, by monitoring the increase in absorbance at 340 nm due to the formation of NADH ( $\epsilon$ 340 is 6220 M<sup>-1</sup> cm<sup>-1</sup>). The reaction mixture contained 0.1 M Tris pH 8.0, 0.1 M KCl, 3 mM EDTA, 2 mM DTT, 0.1 M IMP and enzyme (IMPDH human type II) at a 30 concentration of 15 to 50 nM. This solution is incubated at 37°C for 10 minutes. The reaction is started by adding NAD to a final concentration of 0.1M and the initial rate is measured by following the

linear increase in absorbance at 340 nm for 10 minutes. For reading in a standard spectrophotometer (path length 1 cm) the final volume in the cuvette is 1.0 ml. The assay has also been adapted to a 96 well microtiter 5 plate format; in this case the concentrations of all the reagents remain the same and the final volume is decreased to 200  $\mu$ l.

For the analysis of inhibitors, the compound in question is dissolved in DMSO to a final concentration 10 of 20 mM and added to the initial assay mixture for preincubation with the enzyme at a final volume of 2-5% (v/v). The reaction is started by the addition of NAD, and the initial rates measured as above.  $K_i$  determinations are made by measuring the initial 15 velocities in the presence of varying amounts of inhibitor and fitting the data using the tight-binding equations of Henderson (Henderson, P. J. F. (1972) Biochem. J. 127, 321].

These results are shown in Table III.  $K_i$  20 values are expressed in nM. Category "A" indicates 0.01 to 50 nm activity, category "B" indicates 51-1000 nm activity, category "C" indicates 1001 to 10,000 nm activity, category "D" indicates greater than 10,000 nm activity. The designation "ND" is used where a given 25 compound was not tested.

- 73 -

Table III

|   | Cmpd<br># | K <sub>i</sub><br>(nM) |  | Cmpd<br># | K <sub>i</sub><br>(nM) |  | Cmpd<br># | K <sub>i</sub><br>(nM) |
|---|-----------|------------------------|--|-----------|------------------------|--|-----------|------------------------|
| 5 | 1         | C                      |  | 40        | C                      |  | 78        | B                      |
|   | 2         | C                      |  | 41        | C                      |  | 79        | B                      |
|   | 3         | B                      |  | 42        | B                      |  | 80        | C                      |
|   | 4         | D                      |  | 43        | B                      |  | 81        | C                      |
|   | 5         | C                      |  | 44        | --                     |  | 82        | C                      |
|   | 6         | C                      |  | 45        | C                      |  | 83        | B                      |
|   | 7         | B                      |  | 46        | B                      |  | 84        | B                      |
|   | 8         | C                      |  | 47        | B                      |  | 85        | B                      |
|   | 9         | C                      |  | 48        | C                      |  | 86        | C                      |
|   | 10        | C                      |  | 49        | C                      |  | 87        | D                      |
|   | 11        | C                      |  | 50        | D                      |  | 88        | C                      |
|   | 12        | C                      |  | 51        | D                      |  | 89        | C                      |
|   | 13        | C                      |  | 52        | C                      |  | 90        | C                      |
|   | 14        | C                      |  | 53        | C                      |  | 91        | C                      |
|   | 15        | C                      |  | 54        | C                      |  | 92        | C                      |
|   | 16        | C                      |  | 55        | A                      |  | 93        | A                      |
|   | 17        | B                      |  | 56        | B                      |  | 94        | B                      |
|   | 18        | C                      |  | 57        | B                      |  | 95        | C                      |
|   | 19        | C                      |  | 58        | C                      |  | 96        | B                      |
|   | 20        | C                      |  | 59        | A                      |  | 97        | A                      |
|   | 21        | C                      |  | 60        | B                      |  | 98        | B                      |
|   | 22        | C                      |  | 61        | D                      |  | 99        | A                      |
|   | 23        | C                      |  | 62        | C                      |  | 100       | B                      |
|   | 24        | B                      |  | 63        | C                      |  | 101       | C                      |
|   | 25        | C                      |  | 64        | B                      |  | 102       | C                      |
|   | 26        | C                      |  | 65        | B                      |  | 103       | C                      |
|   | 27        | C                      |  | 66        | C                      |  | 104       | C                      |
|   | 28        | C                      |  | 67        | C                      |  | 105       | B                      |
|   | 29        | D                      |  | 68        | B                      |  | 106       | B                      |
|   | 30        | C                      |  | 69        | B                      |  | 107       | A                      |
|   | 31        | D                      |  | 70        | C                      |  | 108       | B                      |
|   | 32        | D                      |  | 71        | C                      |  | 109       | B                      |
|   | 33        | D                      |  | 72        | C                      |  | 110       | B                      |
|   | 34        | C                      |  | 73        | B                      |  | 111       | A                      |
|   | 35        | C                      |  | 74        | B                      |  | 112       | B                      |
|   | 36        | C                      |  | 75        | B                      |  | 113       | A                      |
|   | 37        | C                      |  | 76        | C                      |  | 114       | B                      |
|   | 38        | D                      |  | 77        | B                      |  | 115       | B                      |
|   | 39        | D                      |  |           |                        |  |           |                        |

- 74 -

| Cmpd<br># | K <sub>i</sub><br>(nM) |
|-----------|------------------------|-----------|------------------------|-----------|------------------------|-----------|------------------------|
| 116       | A                      | 129       | A                      | 142       | A                      | 155       | A                      |
| 117       | B                      | 130       | A                      | 143       | B                      | 156       | A                      |
| 118       | C                      | 131       | A                      | 144       | B                      | 157       | B                      |
| 119       | A                      | 132       | A                      | 145       | A                      | 158       | B                      |
| 120       | A                      | 133       | A                      | 146       | A                      | 159       | A                      |
| 121       | A                      | 134       | A                      | 147       | A                      | 160       | A                      |
| 122       | A                      | 135       | A                      | 148       | A                      | 161       | A                      |
| 123       | A                      | 136       | A                      | 149       | A                      | 162       | A                      |
| 124       | A                      | 137       | B                      | 150       | A                      | 163       | B                      |
| 125       | A                      | 138       | A                      | 151       | B                      | 164       | B                      |
| 126       | A                      | 139       | B                      | 152       | B                      | 165       | A                      |
| 127       | A                      | 140       | A                      | 153       | A                      | 166       | D                      |
| 128       | A                      | 141       | A                      | 154       | A                      | 167       | B                      |
|           |                        |           |                        |           |                        | 168       | B                      |

Example 15

## Anti-Viral Assays

5

The anti-viral efficacy of compounds may be evaluated in various in vitro and in vivo assays. For example, compounds may be tested in in vitro viral replication assays. In vitro assays may employ whole 10 cells or isolated cellular components. In vivo assays include animal models for viral diseases. Examples of such animal models include, but are not limited to, rodent models for HBV or HCV infection, the Woodchuck model for HBV infection, and chimpanzee model for HCV 15 infection.

While we have described a number of embodiments of this invention, it is apparent that our basic constructions may be altered to provide other embodiments which utilize the products and methods of 20 this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific

- 75 -


embodiments which have been presented by way of example.

- 76 -

CLAIMS

We claim:

1. A method of inhibiting IMPDH activity in  
 5 a mammal comprising the step of administering to said  
 mammal a compound of the formula:



wherein:


A is selected from:

10  $(C_1-C_6)$ -straight or branched alkyl, or  $(C_2-C_6)$ -straight or branched alkenyl or alkynyl; and A  
 optionally comprises up to 2 substituents, wherein:

the first of said substituents, if present,  
 is selected from  $R^1$  or  $R^3$ , and

15 the second of said substituents, if present,  
 is  $R^1$ ;

B is a saturated, unsaturated or partially  
 saturated monocyclic or bicyclic ring system optionally  
 comprising up to 4 heteroatoms selected from N, O, or S  
 20 and selected from the formulae:



25 wherein each X is the number of hydrogen atoms  
 necessary to complete proper valence;

- 77 -

and B optionally comprises up to 3 substituents,  
wherein:

the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

5 the second of said substituents, if present,  
is selected from R<sup>1</sup> or R<sup>4</sup>, and

the third of said substituents, if present,  
is R<sup>1</sup>; and

D is selected from C(O), C(S), or S(O)<sub>2</sub>;

10 wherein:

each R<sup>1</sup> is independently selected from 1,2-methylenedioxy, 1,2-ethylenedioxy, R<sup>6</sup> or (CH<sub>2</sub>)<sub>n</sub>-Y;

wherein n is 0, 1 or 2; and

Y is selected from halogen, CN, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>,

15 OH, SR<sup>6</sup>, S(O)R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, NH<sub>2</sub>, NHR<sup>6</sup>, N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>R<sup>8</sup>, COOH,  
COOR<sup>6</sup> or OR<sup>6</sup>;

each R<sup>2</sup> is independently selected from (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>)-straight or branched alkenyl or alkynyl; and each R<sup>2</sup> optionally comprises up to 2 substituents, wherein:

20

the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup>, and

the second of said substituents, if present,  
is R<sup>1</sup>;

25 R<sup>3</sup> is selected from a monocyclic or a bicyclic ring system consisting of 5 to 6 members per ring, wherein said ring system optionally comprises up to 4 heteroatoms selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to any of said N, O, or S heteroatoms is

optionally substituted with C(O); and each R<sup>3</sup> optionally comprises up to 3 substituents, wherein:

the first of said substituents, if present, is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

5 the second of said substituents, if present, is selected from R<sup>1</sup> or R<sup>4</sup>, and

the third of said substituents, if present, is R<sup>1</sup>;

each R<sup>4</sup> is independently selected from OR<sup>5</sup>,

10 OC(O)R<sup>6</sup>, OC(O)R<sup>5</sup>, OC(O)OR<sup>6</sup>, OC(O)OR<sup>5</sup>, OC(O)N(R<sup>6</sup>)<sub>2</sub>,

OP(O)(OR<sup>6</sup>)<sub>2</sub>, SR<sup>6</sup>, SR<sup>5</sup>, S(O)R<sup>6</sup>, S(O)R<sup>5</sup>, SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>5</sup>,

SO<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, SO<sub>3</sub>R<sup>6</sup>, C(O)R<sup>5</sup>, C(O)OR<sup>5</sup>, C(O)R<sup>6</sup>,

C(O)OR<sup>6</sup>, NC(O)C(O)R<sup>6</sup>, NC(O)C(O)R<sup>5</sup>, NC(O)C(O)OR<sup>6</sup>,

NC(O)C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)N(OR<sup>6</sup>)R<sup>6</sup>,

15 C(O)N(OR<sup>6</sup>)R<sup>5</sup>, C(NOR<sup>6</sup>)R<sup>6</sup>, C(NOR<sup>6</sup>)R<sup>5</sup>, N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>C(O)R<sup>1</sup>,

NR<sup>6</sup>C(O)R<sup>6</sup>, NR<sup>6</sup>C(O)R<sup>5</sup>, NR<sup>6</sup>C(O)OR<sup>6</sup>, NR<sup>6</sup>C(O)OR<sup>5</sup>,

NR<sup>6</sup>C(O)N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>C(O)NR<sup>5</sup>R<sup>6</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>5</sup>,

NR<sup>6</sup>SO<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, N(OR<sup>6</sup>)R<sup>6</sup>, N(OR<sup>6</sup>)R<sup>5</sup>,

P(O)(OR<sup>6</sup>)N(R<sup>6</sup>)<sub>2</sub>, and P(O)(OR<sup>6</sup>)<sub>2</sub>;

20 each R<sup>5</sup> is a monocyclic or a bicyclic ring system consisting of 5 to 6 members per ring, wherein said ring system optionally comprises up to 4 heteroatoms selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to

said N, O or S maybe substituted with C(O); and each p<sup>5</sup> 25 optionally comprises up to 3 substituents, each of

which, if present, is R<sup>1</sup>;

- 79 -

each R<sup>6</sup> is independently selected from H, (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>) straight or branched alkenyl; and

each R<sup>6</sup> optionally comprises a substituent that is R<sup>7</sup>;

5 R<sup>7</sup> is a monocyclic or a bicyclic ring system consisting of 5 to 6 members per ring, wherein said ring system optionally comprises up to 4 heteroatoms selected from N, O, or S, and wherein a CH<sub>2</sub> adjacent to said N, O or S maybe substituted with C(O); and each R<sup>7</sup>  
10 optionally comprises up to 2 substituents independently chosen from H, (C<sub>1</sub>-C<sub>4</sub>)-straight or branched alkyl, or (C<sub>2</sub>-C<sub>4</sub>) straight or branched alkenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH<sub>2</sub>)<sub>n</sub>-Z;

wherein n is 0, 1 or 2; and

15 Z is selected from halogen, CN, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, OH, S(C<sub>1</sub>-C<sub>4</sub>)-alkyl, SO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl, N((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, N((C<sub>1</sub>-C<sub>4</sub>)-alkyl)R<sup>8</sup>, COOH, C(O)O(C<sub>1</sub>-C<sub>4</sub>)-alkyl or O(C<sub>1</sub>-C<sub>4</sub>)-alkyl; and

20 R<sup>8</sup> is an amino protecting group; and

wherein any carbon atom in any A, R<sup>2</sup> or R<sup>6</sup> is optionally replaced by O, S, SO, SO<sub>2</sub>, NH, or N(C<sub>1</sub>-C<sub>4</sub>)-alkyl.


25 2. The method according to claim 1, wherein in said compound, B has from 0 to 2 substituents.

3. The method according to claim 1 or 2, wherein in said compound, B comprises at least a first 30 substituent and wherein said first substituent is R<sup>5</sup>.

4. The method according to claim 3, wherein in said compound, B is a monocyclic aromatic ring and said first substituent of B is a monocyclic aromatic 5 ring.

5. A method of inhibiting IMPDH activity in a mammal comprising the step of administering to said mammal a compound of the formula:

10



wherein:

D and each B are defined as in claim 1.

15

6. The method according to claim 5, wherein in said compound, at least one B has from 0 to 2 substituents.

20


7. The method according to claim 5 or 6, wherein in said compound, one B comprises at least a first substituent and wherein said first substituent is R<sup>5</sup>.

25

8. The method according to claim 7, wherein in said compound, said B is a monocyclic aromatic ring and said first substituent of said B is a monocyclic aromatic ring.

30 9. A compound of the formula:  
wherein:

- 81 -




A, D, and B are as defined in claim 1;

E is O or S; and

5 G and G' are independently selected from R<sup>1</sup> or H.

10. A compound of the formula:




wherein:

10 B and D are as defined in claim 5;

E, G and G' are as defined in claim 9;

B' is a saturated, unsaturated or partially saturated monocyclic or bicyclic ring system optionally comprising up to 4 heteroatoms selected from N, O, or S

15 and selected from the formulae:



and B' optionally comprises up to 3 substituents,

20 wherein:

- 82 -


the first of said substituents, if present,  
is selected from R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> or R<sup>5</sup>,

the second of said substituents, if present,  
is selected from R<sup>1</sup> or R<sup>4</sup>, and

5 the third of said substituents, if present,  
is R<sup>1</sup>;

wherein X, R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined in claim 5;  
wherein if B is unsubstituted phenyl and all of said  
substituents present are on B' are R<sup>1</sup>, then at least  
10 one of said R<sup>1</sup> substituents is not chloro, bromo or  
iodo; and wherein B and B' are not simultaneously  
unsubstituted phenyl.

11. The compound according to claim 10  
15 having the formula:



wherein:

K is selected from R<sup>1</sup> and R<sup>4</sup>; and

J is selected from R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup>.

20

12. The compound according to claim 11,  
wherein D is -C(O)-.

13. The compound according to claim 11,  
25 wherein E is oxygen.

14. The compound according to claim 11,  
wherein J is NR<sup>6</sup>C(O)R<sup>5</sup> or NR<sup>6</sup>C(O)R<sup>6</sup>.

- 83 -

15. The compound according to claim 14,  
wherein J is  $NR^6C(O)R^6$ .

5 16. The compound according to claim 15,  
wherein J is  $N(CH_3)C(O)R^6$ .

17. The compound according to claim 11,  
wherein K is  $(CH_2)_n-Y$ .

10

18. The compound according to claim 17,  
wherein K is  $OCH_3$ .

19. The compound according to claim 11,  
15 wherein G is hydrogen.

20. The compound according to claim 16,  
wherein:

D is  $-C(O)-$ ;  
20 E is oxygen;  
K is  $OCH_3$ ; and  
G is hydrogen.

21. The compound according to claim 11,  
25 wherein J is  $R^2$ .

22. The compound according to claim 21,  
wherein E is oxygen.

30 23. The compound according to claim 21,  
wherein J is  $R^2$  substituted with  $R^4$ .

- 84 -

24. The compound according to claim 23,  
wherein  $R^4$  is  $NR^6C(O)OR^5$  or  $NR^6C(O)OR^6$ .

25. The compound according to claim 21,  
5 wherein K is  $(CH_2)_n-Y$ .


26. The compound according to claim 25,  
wherein K is  $OCH_3$ .

10 27. The compound according to claim 21,  
wherein:

D is  $-C(O)-$ ;  
E is oxygen;  
K is  $OCH_3$ ; and

15 G is hydrogen.

28. A compound of the formula:



20

wherein K is selected from  $R^1$  and  $R^4$ ; and  
A, D,  $R^1$  and  $R^4$  are each independently as defined in  
claim 1.

25 29. The compound according to claim 28,  
wherein D is  $-C(O)-$ .

- 85 -


30. The compound according to claim 28,  
wherein A is a monocyclic aromatic ring substituted  
with 1-2 substituents selected from the group  
consisting of  $NR^6C(O)R^6$ ,  $NR^6C(O)R^5$ ,  $CH_2NR^6C(O)OR^6$ , and  
5  $CH_2NR^6C(O)OR^5$ .

31. The compound according to claim 30,  
wherein A is a monocyclic aromatic ring substituted  
with 1-2 substituents selected from the group  
10 consisting of  $CH_2NR^6C(O)OR^6$  and  $CH_2NR^6C(O)OR^5$ .

32. The compound according to claim 28,  
wherein K is  $(CH_2)_n-Y$ .

15 33. The compound according to claim 32,  
wherein K is  $OCH_3$ .

34. A compound according to the formula:



20 wherein:

D is selected from  $C(O)$ ,  $C(S)$  and  $S(O)_2$ ;

K is selected from  $R^1$  and  $R^4$ ; and

J is selected from  $R^1$ ,  $R^2$ , and  $R^4$ .

25 35. The compound according to claim 34,  
wherein D is  $-C(O)-$ .

- 86 -

36. The compound according to claim 34,  
wherein J is NR<sup>6</sup>C(O)R<sup>5</sup> or NR<sup>6</sup>C(O)R<sup>6</sup>.

5 37. The compound according to claim 34,  
wherein K is (CH<sub>2</sub>)<sub>n</sub>-Y.

38. The compound according to claim 37,  
wherein K is OCH<sub>3</sub>.

10


39. The compound according to claim 10  
selected from the group consisting of compounds 1-27,  
29-31, 39-51, 53-69, 71-86, 88-89, 91-102 and 104-162  
in Tables IA, IB and IC.

15


40. The compound according to claim 28  
selected from the group consisting of compounds 163-168  
in Table IIB.

20

41. A pharmaceutical composition comprising:  
a. a compound of the formula:



or



25 in an amount effective to inhibit IMPDH activity,  
wherein A, B and D are as defined in claim 1;

b. an additional agent selected from  
an immunosuppressant, an anti-cancer agent, an anti-  
viral agent, antiinflammatory agent, antifungal agent,

- 87 -

antibiotic, or an anti-vascular hyperproliferation agent;

5 c. a pharmaceutically acceptable adjuvant.

42. The composition according to claim 41, wherein in said compound, at least one B comprises at least a first substituent and wherein said first substituent is R<sup>5</sup>.

10

43. A pharmaceutical composition comprising:  
a. a compound according to any one of claims 9 to 40 in an amount effective to inhibit IMPDH activity; and

15

b. a pharmaceutically acceptable adjuvant.

44. The pharmaceutical composition according to claim 43, additionally comprising an additional 20 agent selected from an immunosuppressant, an anti-cancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation agent.

25

45. A method for treating or preventing IMPDH mediated disease in a mammal comprising the step of administering to said mammal a composition according to claim 41.

30

46. A method for treating or preventing IMPDH mediated disease in a mammal comprising the step of administering to said mammal a composition according to claim 43.

47. The method according to claim 46, wherein said composition additionally comprises an agent selected from an immunosuppressant, an anti-  
5 cancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation agent

48. The method according to any one of claims  
10 45 to 47, wherein said method is used to suppress an immune response and wherein said additional agent, if present, is an immunosuppressant.

49. The method according to claim 48,  
15 wherein said IMPDH mediated disease is an autoimmune disease.

50. The method according to any one of claims 45 to 47, wherein the IMPDH mediated disease is  
20 a viral disease and wherein said additional agent, if present, is an anti-viral agent.

51. The method according to any one of claims 45 to 47, wherein the IMPDH mediated disease is  
25 a vascular disease and wherein said additional agent, if present, is an anti-vascular hyperproliferation agent.

52. The method according to any one of claims 45 to 47, wherein the IMPDH mediated disease is  
30 cancer and wherein said additional agent, if present, is an anti-cancer agent.

- 89 -

53. The method according to any one of claims  
45 to 47, wherein the IMPDH mediated disease is an  
inflammatory disease and wherein said additional agent,  
5 if present, is an antiinflammatory agent.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/06623

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D263/32 A61K31/42 C07D413/12 C07C275/28 C07C275/34  
C07C275/42

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| A        | US 5 380 879 A (ERIC B. SJOGREN ) 10<br>January 1995<br>cited in the application<br>see column 17-column 23<br>see column 2, line 20 - line 55<br>----- | 1-53                  |

Further documents are listed in the continuation of box C.  Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

|   |  |
|---|--|
| 1 Date of the actual completion of the international search<br><br>24 July 1997   | Date of mailing of the international search report<br><br>04.08.97 |
| Name and mailing address of the ISA<br><br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax (+31-70) 340-3016 | Authorized officer<br><br>Henry, J                                 |

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/06623

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim(s) 1-8, 45-53 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
In view of the large number of compounds which are defined by the wording of the claims, the search has been performed on the general idea and compounds mentioned in the examples of the description.  
Claims searched incompletely: 1-53
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/06623

| Patent document cited in search report | Publication date | Patent family member(s) |           | Publication date |
|--|------------------|-------------------------|-----------|------------------|
| US 5380879 A                           | 10-01-95         | AU                      | 1916995 A | 04-09-95         |
|  |                  | CA                      | 2183529 A | 24-08-95         |
|  |                  | CN                      | 1143366 A | 19-02-97         |
|  |                  | EP                      | 0745074 A | 04-12-96         |
|  |                  | FI                      | 963219 A  | 11-10-96         |
|  |                  | WO                      | 9522535 A | 24-08-95         |
|  |                  | US                      | 5441953 A | 15-08-95         |

Form PCT/ISA/210 (patent family annex) (July 1992)